Asymmetric Dihydroxylation of β , γ -Unsaturated Carboxylic Esters with Trisubstituted C=C Bonds – Enantioselective Syntheses of Trisubstituted γ -Butyrolactones

Tobias Kapferer^[a] and Reinhard Brückner^{*[a]}

Keywords: Asymmetric dihydroxylation / Butyrolactones / β,γ-Unsaturated carboxylic esters / Stereoselective synthesis / Wolff rearrangement

 β , γ -Unsaturated esters with stereodefined trisubstitued C=C double bonds were prepared by the Arndt–Eistert homologation of α , β -unsaturated carboxyl halides, by two-step methoxycarbonylation of allylbarium reagents, by deconjugation of α , β -unsaturated esters, and by Horner–Wadsworth–Emmons variants of the Stobbe condensation. Sharpless asymmetric dihydroxylation of the β , γ -unsaturated esters, followed by spontaneous cyclization, afforded β -hydroxy- γ -lac-

tones in moderate to good yields and with enantiomeric excesses of up to 97%. Similarly, tetrahydroxy- γ -lactones were obtained from diunsaturated esters; these lactones were converted into a bislactone and an unsaturated β -hydroxy γ -lactone.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)

Introduction

γ-Lactones are a commonly encountered structural motif in nature^[1] and synthesis (both as targets and synthetic intermediates). This is particularly true if these γ-lactones are enantiomerically pure. Accordingly, a considerable body of methods for synthesizing such lactones with saturated ("butanolides"^[2]) or α,β-unsaturated rings ("Δ³-butenolides"^[3]) has been developed over the years. They include a straightforward asymmetric synthesis by our group, based on Sharpless' asymmetric dihydroxylation ("AD reaction")^[4] of β,γ-unsaturated carboxylic esters **1** (Scheme 1).^[5] This approach provides γ-lactones **3** with *ees* of typically 94– 98%, in good yields and a single step.^[5–7]

In all previous studies by this group^[5b,6,7] (with a single exception;^[8] vide infra) and by others^[5a,9] the AD reaction has been performed upon β , γ -unsaturated carboxylic esters **1** containing disubstituted $C^{\beta}=C^{\gamma}$ double bonds (Scheme 1: $\mathbb{R}^2 = \mathbb{H}$), resulting in the formation of γ -monoalkyl- or γ -monoaryl- β -hydroxy- γ -lactones **3** ($\mathbb{R}^2 = \mathbb{H}$). A logical extension of this concept appeared to be analogous AD reactions of β , γ -unsaturated carboxylic esters **1** containing *tri*substituted $C^{\beta}=C^{\gamma}$ double bonds (Scheme 1: $\mathbb{R}^2 \neq \mathbb{H}$). They should provide β , γ -dialkyl- and γ , γ -dialkyl- β -hydroxy- γ -lactones **3** ($\mathbb{R}^2 \neq \mathbb{H}$) as well as their aryl-containing congeners. This paper describes how this concept was put into practice.

A prerequisite for this study was the acquisition of model esters for the AD reaction as pure stereoisomers with re-

 [a] Institut für Organische Chemie und Biochemie, Albert-Ludwigs-Universität,
 Albertstr. 21, 79104 Freiburg, Germany Fax: +49-761-2036100

E-mail: reinhard.brueckner@organik.chemie.uni-freiburg.de



Scheme 1. Dihydroxylation strategy for the asymmetric synthesis of γ -lactones.

spect to their $C^{\beta}=C^{\gamma}$ double bonds; otherwise AD reactions of these esters would give mixtures of lactone diastereomers. Stereodefined β,γ -unsaturated esters were obtained by the following approaches: Arndt–Eistert homologation of α,β -unsaturated acids [7–10, (*E*)- and (*Z*)-14], carboxylation of allyl barium compounds [(*E*)- and (*Z*)-18], Horner–Wadsworth–Emmons reactions ("HWE reactions") [(*E*)-31–34, (*Z*)-31, (*Z*)-33 and -34], and deprotonation/reprotonation of α,β -unsaturated carboxylic esters (24, 25).

Results and Discussion

Preparation of the AD Precursors

The majority of our syntheses of stereochemically pure β , γ -unsaturated carboxylic esters were achieved by Arndt– Eistert homologation of analogously substituted α , β -unsat-

urated carboxylic acids.^[10] This approach worked well when starting from the α , β -dialkylated α , β -unsaturated acids **4a**– **d** (Scheme 2) and the β , β -dialkylated α , β -unsaturated acids (*E*)- and (*Z*)-**11** (Scheme 3). Acids **4a** and **4b** were obtained by alkaline hydrolyses of the corresponding (*E*)-configured α , β -unsaturated esters (not shown), these in turn being obtained by Wittig reactions.^[11] Acid **4c** was synthesized as described,^[36] whilst acid **4d** is commercially available. Acids (*E*)- and (*Z*)-**11** were produced through *cis*-selective carbocuprations of appropriately substituted alkynoic acids.^[12]



Scheme 2. Arndt–Eistert homologation of α , β -dialkyl α , β -unsaturated carboxyl bromides. Reagents and conditions: (a) For **5a–c**: (COBr)₂ (1.01 equiv.), no solvent, -15 °C, overnight; for **5d**: 1-bromo-2-(dimethylamino)-2-methyl-1-propene (1.0 equiv.), CH₂Cl₂, 0 °C \rightarrow room temp., 1 h. (b) CH₂N₂ (1.0 equiv.), *i*Pr₂NEt (1.1 equiv.), Et₂O, 0 °C \rightarrow room temp., 2 h; **6a**: 28% over the two steps; **6b**: 83% over the two steps; **6c**: 81% over the two steps; **6d**: 52% over the two steps. (c) AgOBz, NEt₃, MeOH, room temp., 5 h; 7 (*E*:*Z* = 100:0): 76%; **8** (*E*:*Z* = 100:0): 77%; **9** (*E*:*Z* = 100:0): 86%.

It is known that the acylation of diazomethane with activated α,β -unsaturated carboxylic acids may be accompanied by pyrazoline formation through a 1,3-dipolar cycloaddition of diazomethane to the electron-deficient $C^{\alpha}=C^{\beta}$ bond.^[13] This competition was detrimental to formation of the desired diazo ketones **6a–d** from the acid chlorides obtained from the α,β -dialkylated α,β -unsaturated acids **4a–d** (Scheme 2). In contrast, pyrazoline formation was insignificant in diazomethane treatment of acid chlorides (*E*)- and (*Z*)-**12** [\rightarrow diazo ketones (*E*)- and (*Z*)-**13**, respectively; Scheme 3]. With use of the α,β -unsaturated acid bromides **5a–d** – rather than the analogous chlorides – as acylating agents, however, diazo ketones **6a–d** were also generated successfully (Scheme 2).

Silver benzoate-induced Wolff rearrangements^[14] of diazo ketones **6a–d**, (*E*)-**13**, and (*Z*)-**13** in methanol furnished



Scheme 3.^[8] Arndt–Eistert homologation of β , β -dialkyl α , β -unsaturated carboxylic acid chlorides. Reagents and conditions: (a) SOCl₂ (1.0 equiv.), DMF (cat.), CH₂Cl₂, 0 °C \rightarrow room temp., 3 h. (b) CH₂N₂ (2.0 equiv.), *i*Pr₂NEt (1.0 equiv.), Et₂O, 0 °C \rightarrow room temp., 1 h: 55% over the two steps. (c) AgOBz (0.3 equiv.), NEt₃ (4.7 equiv.), MeOH, room temp., 5 h; 88% (*E*:*Z* = 100:0). (*Z*)-14: *Z*:*E* = 100:0.

the desired β , γ -unsaturated methyl esters 7–10, (*E*)-13, and (*Z*)-13, respectively. These were produced with complete retention of the C=C double bond configuration.

Geraniol [(*E*)-15] and nerol [(*Z*)-15] were converted into the analogous chlorides (*E*)- and (*Z*)-15, respectively, through treatment with mesyl chloride and triethylamine^[15] (Scheme 4). The corresponding barium derivatives – obtained by treatment with Rieke barium (from anhydrous barium iodide and lithium biphenylide) – were C₁-extended through addition to carbon dioxide. This afforded the β , γ unsaturated carboxylic acids (*E*)- and (*Z*)-17 stereospecifically, as reported by Yamamoto et al.^[16] Methyl ester formation with (trimethylsilyl)diazomethane^[17] in benzene/ methanol gave the desired β , γ -unsaturated esters (*E*)- and (*Z*)-18 in 96% yield and diastereomerically pure within the limits of ¹H NMR detection.



Scheme 4. Methoxycarbonylation of allylbarium reagents. Reagents and conditions: (a) MeSO₂Cl (1.5 equiv.), pentane, $-5 \,^{\circ}$ C, 30 min; pyridine (2.0 equiv.), pentane, room temp., 14 h; 83% (ref.^[15] 74%). (b) BaI₂ (2.2 equiv.), Li biphenylide (4.4 equiv.), THF, $-78 \,^{\circ}$ C, 30 min; CO₂ (gaseous), 30 min; 61% (ref.^[16] 87%). (c) Me₃SiCHN₂ (1.3 equiv.), MeOH/benzene (1:3.6), room temp., 1 h; 96% (*E*:*Z* = 100:0). (*Z*)-**18**: *Z*:*E* = 100:0.

We found the syntheses of ester (E)-18 shown in Scheme 4 superior to carboxymethylation of either allyl

chloride (*E*)-16 or the analogous allyl phosphate with CO/ methanol in the presence of $Pd_2(dba)_3/NaOMe.^{[18]}$ This kind of reaction was poorly stereoselective in our hands; chloride (*E*)-16, for example, gave (*E*)-18:(*Z*)-18 = 73:27 (74%).

β,γ-Unsaturated esters $24^{[19]}$ and $25^{[20]}$ contain endocyclic C^β=C^γ bonds: namely, a cyclopentenyl and a cyclohexenyl moiety, respectively (Scheme 5). These compounds were obtained by deconjugation of the isomeric *α*,β-unsaturated esters $22^{[19]}$ and 23,^[20] respectively, these in turn being obtained by HWE reactions between the appropriate cycloalkanones and phosphonate 21.^[21] Deconjugation was achieved by subsequent deprotonation with LDA followed by reprotonation with aqueous NH₄Cl and glacial acetic acid, respectively.



Scheme 5. Formation and deconjugation of α , β -unsaturated esters. Reagents and conditions: (a) NaOMe (1.2 equiv.), methanol, room temp., 12 h, **22**: 93% (as a 90:10 mixture with **24**), **23**: 98%. (b) LDA (1.1 equiv.), THF, -78 °C, 1 h; NH₄Cl (for **24**) or HOAc (for **25**); **24**: 76%, **25**: 78%.

The second largest number of β , γ -unsaturated ester syntheses in this study was obtained by HWE variants of the Stobbe condensation (Scheme 6, Scheme 7). These reactions furnished diethyl diesters (*E*)-**32**, (*E*)-**34**, and (*Z*)-**34** and dimethyl diesters (*Z*)-**31** and (*Z*)-**33**. Subsequent transesterifications of diethyl diesters (*E*)-**32** and (*E*)-**34** with sodium methoxide also gave the dimethyl diesters (*E*)-**31** and (*E*)-**33**.

We tried to establish the $C^{\beta}=C^{\gamma}$ bonds in the described "Stobbe condensation products" stereoselectively by varying the phosphonate moieties in the employed HWE reagents: with a (EtO)₂P(=O) moiety in HWE reagent 28 (Scheme 6) as opposed to a $(PhO)_2P(=O)$ moiety in the HWE reagents 37 and 38^[22] in Scheme 7. The presence of the (EtO)₂P(=O) moiety in HWE reagent 28 made the olefinations of the aliphatic aldehyde 29 and of benzaldehyde (30) (E)-selective to extents of 82:18 (32) and 93:7 (34), respectively (Scheme 6). The $(PhO)_2P(=O)$ -containing HWE reagents 37 and 38^[22] olefinated the same aldehydes with Z: E selectivities between 81:19 (\rightarrow 34) and 67:33 (\rightarrow 31; Scheme 7);^[23] to the best of our knowledge, these last reagents have been used for (Z)-selective succinylidenations for the first time. In all instances, the major unsaturated ester isomer could be obtained isomerically pure by flash chromatography^[24] on silica gel.

AD Reactions

Having made the selected β , γ -unsaturated model esters accessible as single stereoisomers, we proceeded to examine magnitudes of stereocontrol during their AD reactions. In



Scheme 6. (*E*)-selective Horner–Wadsworth–Emmons variant of the Stobbe condensation. Reagents and conditions: (a₁) **26**, NaH (1.0 equiv.), EtOH, 0 °C \rightarrow room temp., 30 min; addition of **27** (1.0 equiv.), 1 h (\rightarrow **28**; not isolated). (a₂) Crude **28**, **29** (1.0 equiv.) or **30** (1.0 equiv.), 4 h [for preparation of (*E*)-**32**] or overnight [for preparation of (*E*)-**34**]; (*E*)-**32**: 61% (*E*:*Z* = 82:18); (*E*)-**34**: 48% (*E*:*Z* = 93:7). (b) NaH (2.0 equiv.), MeOH, room temp., 2 d; 87% (*E*:*Z* = 81:19); (c) same as b), 3 d; 81% (*E*:*Z* = 92:8).



Scheme 7. (*Z*)-selective Horner–Wadsworth–Emmons variant of the Stobbe condensation. Reagents and conditions: (a) **35**, NaH (1.0 equiv.), THF, 0 °C \rightarrow room temp., 30 min, addition of **36** (1.0 equiv.), 3 h; 69% **37**; **38**.^[22] (b) **37** or **38**, NaH (1.0 equiv.), **29** (1.0 equiv.) or **30** (1.0 equiv.), THF, 0 °C \rightarrow room temp., 3 h [for preparation of (*Z*)-**31** and (*Z*)-**33**] or 1 h [for preparation of (*Z*)-**34**]; (*Z*)-**31**: 86% (*Z*:*E* = 80:20); (*Z*)-**33**: 48% (*Z*:*E* = 67:33); (*Z*)-**34**: 79% (*Z*:*E* = 81:19).

order to collect a fairly comprehensive set of data, all AD reactions were performed separately in the presence of the chiral auxiliaries contained in AD mix[®] α [i.e., (DHQ)₂-PHAL] and AD mix[®] β [(DHQD)₂PHAL], routinely using the so-called "improved"^[25] conditions and only occasion-ally oxidant and auxiliary stoichiometries approaching "standard AD conditions".^[26]

All AD results are shown in Table 1, Table 2, and Table 3. Table 1 relates to β , γ -disubstituted esters containing (*E*)-configured R¹–C=C–CH₂–CO₂R³ moieties as substrates, Table 2 to AD reactions of β , γ -disubstituted esters with (*Z*)-configured R¹–C=C–CH₂–CO₂R³ moieties, and Table 3 to the behavior of pairs of *E*,*Z*-isomeric γ -disubstituted β , γ -unsaturated esters under AD conditions.

The AD reactions of β , γ -disubstituted esters with (*E*)configured (cf. footnote [a] of Table 1) R¹–C=C–CH₂– CO₂R³ moieties were reasonably high-yielding (Table 1), the yields for 18 reactions averaging 69% and the peak yield being 87% (Entries 3, 7). The lowest yields, not unexpectedly, resulted from AD reactions with benzylidene succinates (*Z*)-**33** and (*Z*)-**34** (38%, 47%, 49%; Entries 15–17) and with ester **9**, which contains a *tert*-butylated C=C bond (55%, 56%; Entries 9, 10). This appears to reflect an electronic and a steric effect, respectively.

An unusual chemoselectivity of two pairs of AD reactions in Table 1 deserves mention (Entries 3–6). β , γ -Dihydroxy ester **40a** (or its enantiomer **40b**) obtained from cyclopentene **24** did not lactonize at all (Entries 3, 4). Similarly (Entries 5, 6), only ca. 25% of the β , γ -dihydroxy ester **42a** (or its enantiomer **42b**) obtained from cyclohexene **25** cyclized to give γ -lactone **41a** (or its enantiomer **41b**). These observations contrast with the spontaneous and complete lactonization of *all* β , γ -dihydroxy esters previously obtained under AD conditions (Scheme 1). The decreased driving force for lactonization in the cases under scrutiny must be due to the extra strain expected for *trans*-fused *bicyclic* γ lactones.

Table 1. AD reactions^[25] of β_{γ} -unsaturated β_{γ} -disubstituted esters containing (*E*)-configured^[a] R¹-C=C-CH²-CO₂R³ moieties.



[a] This classification is also true for the substrates of Entries 9–14 although their C=C configurations are "(Z)" by the Cahn–Ingold– Prelog priority rules. [b] Absolute configurations were not proven but were assigned in accordance with "Sharpless' mnemonic" (ref.^[4c,4g]). [c] Determined by chiral GC and HPLC (details: Experimental Part). [d] Determined after transformation into the corresponding acetonide (without formula number; for details see the Exp. Sect.).

K2OsO2(OH)4 (2 mol-%), phthalazine(auxiliary)2 OH (10 mol-%), and/or K₃Fe(CN)₆ (3.0 equiv.) K2CO3 (3.0 equiv.), MeSO₂NH₂ (1.0 equiv.), (E)-31, (E)-33, (E)-34 49a-51a 49b-51b tBuOH/H2O (1:1), major isomer with major isomer with room temp., 0°C (DHQ)₂PHAL (DHQD)₂PHAL Product^[b] R^2 R^3 R^1 Substrate ee [%][c] Yield [%] Entry Auxiliary (isomer ratio >99:1) 1 DHQ 49a 63 89 iBu (E)-31 CO₂Me Me 2 DHQD 49b 78 88 3 DHQ 50a 82 70 Ph CO₂Me Me (E)-3387 77 4 DHQD 50b 5 DHO 76 51a 84 Ph CO₂Et Et (E)-346 DHQD 90 83 51b

Table 2. AD reactions^[25] of β_{γ} -unsaturated β_{γ} -disubstituted esters containing (Z)-configured^[a] R¹-C=C-CH²-CO₂R³ moieties.

[a] This classification is true for all substrates of this Table even if their C=C configuration is "(*E*)" by the Cahn–Ingold–Prelog priority rules. [b] Absolute configurations were not proven but were assigned in accordance with "Sharpless' mnemonic" (ref.^[4c,4g]). [c] Determined by chiral GC and HPLC (for details see the Exp. Sect.).

The enantiomeric excesses in the AD reactions in Table 1 span a range from 83-85% ee at best (for the γ -phenylated ester 10; Entries 11, 12) to 23% ee at worst (for the cyclohexene-containing ester 25; Entry 5). For most substrates, (DHQD)₂PHAL is a more efficient chiral auxiliary than (DHQ)₂PHAL (Entries 1-14), as usually observed in AD chemistry.^[4] However, the AD reactions of benzylidene succinates (Z)-33 and -34 represent exceptions (Entries 15–18). Also noteworthy is that the AD reaction of cyclopent-annulated ester 24 proceeds with considerably more stereocontrol (66% and 79% ees; Entries 3, 4) than that of the cyclohex-annulated analogue 25 (23% and 44% ees; Entries 5, 6). The absolute configurations of the products depicted in Table 1 were not elucidated experimentally but were assigned on the basis of Sharpless' "mnemonic aid",^[4c,4g] which is believed to predict correctly the C-OH bond orientations resulting from the *trans*-configured R^1 -C=C- R^2 substructure of any AD substrate containing it.

The AD reactions of β , γ -disubstituted esters containing (*Z*)-configured (cf. footnote [a], Table 2) R¹–C=C–CH₂–CO₂R³ moieties are summarized in Table 2. The configurations of the resulting γ -lactones were again not determined experimentally but assigned on the basis of Sharpless' "mnemonic aid".^[4c,4g] The yields and *ees* of the AD products in Table 2 were consistently higher than those observed on starting from the isomeric substrates (Table 1, Entries 13–18). As almost always,^[4] (DHQD)₂PHAL was more powerful than (DHQ)₂PHAL as a chiral auxiliary. Consistently with this, the highest *ee* (90%) was observed in

the $(DHQD)_2PHAL$ -mediated AD of benzylidenesuccinate (*E*)-**34**.

AD reactions of two pairs of *E*,*Z*-isomeric γ , γ -disubstituted β , γ -unsaturated esters [(*E*)- and (*Z*)-**14**,^[8] (*E*)- and (*Z*)-**18**] proceeded with yields around 75–90% (Table 3). Esters (*E*)- and (*Z*)-**18** underwent dihydroxylation at *both* C=C bonds, giving rise to the trihydroxy- γ -lactones **53** and **55**.

Half of the ees of the AD reactions summarized in Table 3 were in the nineties (Entries 1, 2, 7, 8), half in the eighties (Entries 3-6). Of the monounsaturated substrate isomers (E)- and (Z)-14, the former (Entries 1, 2) reacted with higher enantioselectivity than the latter (Entries 5, 6): (*E*)-14 \rightarrow 97% *ee* in the presence of (DHQD)₂PHAL vs. (Z)-14 \rightarrow 85% ee; (E)-14 \rightarrow 91% ee in the presence of $(DHQ)_2PHAL$ vs. (Z)-14 $\rightarrow 80\%$ ee. For the diunsaturated isomeric substrates (E)- and (Z)-18, this order was reversed, with the (E) isomer (Entries 3, 4) reacting less enantioselectively than the (Z) isomer (Entries 7, 8): (E)-18 \rightarrow 82% ee in the presence of (DHQD)₂PHAL vs. (Z)-18 \rightarrow 93% ee; (E)-18 \rightarrow 83% ee in the presence of (DHQ)₂PHAL vs. (Z)- $18 \rightarrow 90\%$ ee. These juxtapositions imply the following: (i) the Me₂C=CH–CH₂ moiety in the di-unsaturated substrate 18 is dihydroxylated as rapidly as - or even more rapidly than – the $C^{\gamma}=C^{\beta}H-CH_{2}-CO_{2}Me$ moiety, and (*ii*) the resulting Me₂C(OH)-CH(OH)-CH₂ moiety exerts some substrate control over stereoselectivity during the (remainder) of the dihydroxylation of the $C^{\gamma}=C^{\beta}H-CH_{2}-CO_{2}Me$ moiety, opposing reagent control for the (E)-olefin ("misTable 3. AD reactions ("compromise stoichiometry" between the quantities of ref.^[26] and ref.^[25]) of β , γ -unsaturated γ -disubstituted esters [pairs of (*E*)- and (*Z*) isomers].



[a] Absolute configurations were assigned by "Sharpless' mnemonic" (ref.^[4c,4g]); moreover, they are consistent with the independently assigned absolute configurations of the β -hydroxy- γ -methyl- γ -pentyl- γ -butyrolactone stereoisomers obtained by analogous AD reactions (ref.^[8]). [b] Determined by chiral GC; for details see Experimental Part. [c] This moiety was also dihydroxylated during the AD reaction. [d] Twice as much of each reagent was used as indicated in the equation. [e] Determined after transformation into **57a** and **57b**, respectively (Scheme 8). [f] Determined after transformation into **59a** and **59b**, respectively (Scheme 9).

matched case") and reinforcing it for the (Z)-olefin ("matched case").

The monohydroxy lactone **54a** (80% *ee*; Table 3, Entry 5) and its enantiomer **54b** (85% *ee*, Entry 1) had been employed previously for elucidation of the 3D structure of a butenolide from the moss *Plagiomnium undulatum* by synthesis.^[8] The trihydroxy lactones **53** and **55** were carried on as summarized in Scheme 8 and Scheme 9, respectively. These transformations served two purposes: (*i*) determination of the stereochemical purity of the lactone moiety, and (*ii*) preparation of nonracemic β -hydroxy- γ -lactones containing an additional functional group in one γ -substituent.

Trihydroxy lactone **53a** and its enantiomer **53b** – both derived from methyl geranylcarboxylate – were consecutively subjected to glycol cleavage^[27] and PCC oxidation of the resulting lactols^[28] (Scheme 8), affording bislactone **57a** and its enantiomer **57b**, respectively. We needed these compounds chiefly for analytical purposes – namely, *ee* determination (83 and 82%, respectively) – though their syntheses also represent a straightforward enantioselective route to a structural motif that might otherwise be difficult to obtain.



Scheme 8. Bislactone synthesis from butyrolactone **53a** and its enantiomer. Reagents and conditions: (a) NaIO₄ (1.1 equiv.), THF, H₂O, room temp., 2 h; 64%, *dr* 79:21. (b) PCC (2.0 equiv.), CH₂Cl₂, room temp., 12 h; 57%.

Trihydroxy lactone **55a** and its enantiomer **55b** – both derived from methyl nerylcarboxylate – rendered the lactone-containing hydroxyaldehydes **58** when subjected to glycol cleavage^[27] (Scheme 9). Obviously, lactol formation



Scheme 9. Unsaturated lactone synthesis from butyrolactone **55a** and its enantiomer. Reagents and conditions: (a) NaIO₄ (1.1 equiv.), EtOAc, H₂O, room temp., 30 min; 94%. (b) Ph₃P=CH₂ (1.6 equiv.), THF, $-5 \,^{\circ}C \rightarrow$ room temp., 1.5 h; 31%.

was hampered by the arising of ring-strain. Wittig methylenation^[11,29] of the aldehyde group furnished the unsaturated γ -lactone **59a** (90% *ee*) and its enantiomer **59b** (93% *ee*).

Conclusions

We have studied the asymmetric dihydroxylation of β , γ unsaturated carboxylic esters with trisubstituted double bonds. Except in those esters in which the $C^{\gamma}=C^{\beta}$ bond was part of a five-membered (namely compound 24) or a sixmembered ring (namely compound 25), each substrate was smoothly converted into the corresponding trisubstituted γ lactone (Table 1-Table 3). Lactone yields were good to excellent (up to 92%, Table 3, Entry 5). Enantiocontrol strongly depended on the substrate, lactone ee values spanning a range from 97% (Table 3, Entry 2) to 23% (Table 1, Entry 5), though half of our AD reactions proceeded with ees > 80%. This shows that our strategy for the construction of enantioenriched γ -lactones through the AD reactions of β , γ -unsaturated carboxylic esters is not limited to the production of disubstituted γ -lactones but is also useful for the synthesis of trisubstituted γ -lactones.

Experimental Section

All reactions were performed in oven-dried (110 °C) glassware under N₂. THF was freshly distilled from K, CH₂Cl₂ was distilled from CaH₂. Diazomethane was prepared as an ethanol-free diethyl ether solution as described in the literature^[30] with the aid of an ALDRICH Diazald[®] Kit; the diazomethane concentrations were determined^[30] prior to use. Products were purified by flash chromatography^[24] on Merck silica gel 60 and were isolated as liquids or oils unless stated differently (only for one enantiomer). Yields refer to analytically pure samples. ¹H [CHCl₃ (δ = 7.26 ppm) as internal standard in CDCl₃. C₆HD₅ (δ = 7.15 ppm) as internal standard in C₆D₆]: Varian Mercury VX 300, Bruker AM 400, and Bruker DRX 500. Integrals are in accordance with assignments; coupling constants are in Hz. The assignments of ¹H NMR resonances refer to the IUPAC nomenclature except within substituents where primed numbers are used. Combustion analyses: E. Hickl, Institut für Organische Chemie und Biochemie, University of Freiburg. MS: Dr. J. Wörth and C. Warth, Institut für Organische Chemie und Biochemie, University of Freiburg. IR spectra: Perkin–Elmer Paragon 1000. Optical rotations were measured with a Perkin–Elmer polarimeter 341 at 589 nm and 20 °C and were calculated by the Drude equation { $[\alpha]_D = (\alpha_{exp} \times 100)/(c \times d)$ }; rotational values are the average of five measurements of α_{exp} in a given solution of the respective sample. Melting points were measured on a Dr. Tottoli apparatus (Büchi) and are uncorrected. The *ee* values were determined by chiral GC with a Carlo Erba Instruments HRC 5160 Mega series apparatus with a Varian CP7502 (β -cyclodextrin/dimethylpolysiloxane) column (isothermal analysis) or by chiral HPLC with a Chiralpak AD (Daicel Chemical Ind. Ltd.) column.

(*E*)-2-Ethylpent-2-enoic Acid (4a):^[31] a) Propionaldehyde (131 mg, 2.25 mmol, 1.3 equiv.) was added to a solution of ethyl 2-(triphenylphosphanylidene)butanoate^[32] (636 mg, 1.69 mmol) in benzene (5 mL). After having been heated at 70 °C for 3.5 h, the mixture was allowed to reach room temperature and stirred overnight. After evaporation in vacuo the residue was purified by flash chromatography (cyclohexane/EtOAc, 60:1) to afford ethyl (*E*)-2-ethylpent-2-enoate^[31] (225 mg, 96%, *E*:*Z* = 96:4): ¹H NMR (300 MHz, CDCl₃): δ = 1.00 (t, $J_{2',1'}$ = 7.5 Hz, 2'-H₃)*, 1.05 (t, $J_{5,4}$ = 7.5 Hz, 5-H₃)*, 1.29 [t, J_{vic} = 7.1 Hz, CO₂CH₂CH₃; (*E*) isomer], superimposed by 1.30 [t, J_{vic} = 7.2 Hz, CO₂CH₂CH₃; (*Z*) isomer], 2.19 (dq, $J_{4,3}$ = $J_{4,5}$ = 7.5, 4-H₂), 2.31 (q, $J_{1',2'}$ = 7.5 Hz, 1'-H₂), 4.19 (q, J_{vic} = 7.1 Hz, CO₂CH₂CH₃), 5.81 [m_c, 3-H; (*Z*) isomer], 6.70 [t, $J_{3,4}$ = 7.5 Hz, 3-H; (*E*) isomer] ppm; * = assignments interchangeable.

b) A solution of LiOH·H₂O (6.64 g, 0.158 mol, 10 equiv.) in H₂O (40 mL) was added to a solution of ethyl (*E*)-2-ethylpent-2-enoate (2.472 g, 15.82 mmol) in MeOH (165 mL). The mixture was heated at 45 °C for 7.5 h and stirred overnight at room temperature. After removal of MeOH in vacuo, the mixture was acidified with HCl (2 M) and extracted with EtOAc (3 × 70 mL). The combined organic extracts were dried with MgSO₄ and the solvents were evaporated in vacuo. The residue was purified by flash chromatography (cyclohexane/EtOAc, 15:1) to afford the title compound (1.604 g, 79%): ¹H NMR (300 MHz, CDCl₃): $\delta = 1.03$ (t, $J_{5,4} = 7.5$ Hz, 5-H₃)*, 1.07 (t, $J_{2',1'} = 7.5$ Hz, 2'-H₃)*, 2.23 (dq, $J_{4,3} = J_{4,5} = 7.4$ Hz, 4-H₂), partly superimposed by 2.32 (q, $J_{1',2'} = 7.4$ Hz, 1'-H₂), 6.87 (t, $J_{3,4} = 7.5$ Hz, 3-H), 11.70 (br.s, CO₂H) ppm; * = assignments interchangeable.

(E)-2,4-Dimethylpent-2-enoic Acid (4b):^[33] a) Isobutyraldehyde (3.732 g, 51.75 mmol, 1.7 equiv.) was added to a solution of ethyl 2-(triphenylphosphanylidene)propionate^[34] (10.84 g, 30.00 mmol) in benzene (30 mL). After having been heated at 70 °C overnight, the mixture was allowed to reach room temperature and the solvents were evaporated in vacuo. The residue was purified by flash chromatography (cyclohexane/EtOAc, 60:1) to afford ethyl (E)-2,4dimethylpent-2-enoate^[35] (4.241 g, 90%, E:Z = 96:4): ¹H NMR (300 MHz, CDCl₃): δ = 0.98 [d, $J_{4-Me,4}$ = $J_{5,4}$ = 6.7 Hz, 4-CH₃, 5-H₃; (Z) isomer], 1.02 [d, $J_{4-Me,4} = J_{5,4} = 6.6$ Hz, 4-CH₃, 5-H₃; (E) isomer], 1.29 (t, $J_{vic} = 7.1 \text{ Hz}$, CO₂CH₂CH₃), 1.83 [d, $J_{allyl} =$ 1.2 Hz, 2-CH₃, (*E*) isomer], 1.87 [d, $J_{allyl} = 1.2$ Hz, 2-CH₃, (*Z*) isomer], 2.63 [dqq, $J_{4,3} = 9.9$, $J_{4,4-Me} = J_{4,5} = 6.6$ Hz, 4-H; (E) isomer], 3.20 [m_c, 4-H, (Z) isomer], 4.16 (q, $J_{vic} = 7.1$ Hz, CO₂CH₂CH₃), 5.68 [incompletely resolved dq, $J_{3,4} = 9.7$, $J_{allyl} = 1.3$ Hz, 3-H; (Z) isomer], 6.56 [incompletely resolved dq, $J_{3,4} = 9.7$, $J_{allyl} = 1.3$ Hz, 3-H; (*E*) isomer] ppm.

b) The title compound (**4b**; 1.153 g, 71%, E:Z = 94:6) was prepared from ethyl (*E*)-2,4-dimethylpent-2-enoate (1.976 g, 12.65 mmol, E:Z = 96:4) in a manner analogous to that specified for **4a**, part b):

¹H NMR (300 MHz, CDCl₃): $\delta = 0.99$ [d, $J_{4.Me,4} = J_{5,4} = 6.6$ Hz, 4-CH₃, 5-H₃; (*Z*) isomer], 1.04 [d, $J_{4.Me,4} = J_{5,4} = 6.7$ Hz, 4-CH₃, 5-H₃; (*E*) isomer], 1.85 [d, $J_{allyl} = 1.3$ Hz, 2-CH₃; (*E*) isomer], 1.89 [d, $J_{allyl} = 1.3$ Hz, 2-CH₃; (*Z*) isomer], 2.67 [dqq, $J_{4,3} = 10.0$, $J_{4,4-Me} = J_{4,5} = 6.6$ Hz, 4-H; (*E*) isomer], 3.35 [dqq, $J_{4,3} = 9.9$, $J_{4,4-Me} = J_{4,5} = 6.6$ Hz, 4-H; (*Z*) isomer], 5.86 [incompletely resolved dq, $J_{3,4} = 9.9$, $J_{allyl} = 1.4$ Hz, 3-H; (*Z*) isomer], 6.72 [dq, $J_{3,4} = 9.8$, $J_{allyl} = 1.3$ Hz, 3-H; (*E*) isomer], 12.05 (br. s, CO₂H) ppm.

(*E*)-2-Ethylpent-2-enoyl Bromide (5a): Oxalyl bromide (2.96 mL, 6.80 g, 31.5 mmol, 1.01 equiv.) and DMF (cat.) were added at -15 °C to (*E*)-2-ethylpent-2-enoic acid (4a; 4.00 g, 31.2 mmol). After stirring overnight, the crude product was converted into 6a without further purification.

(*E*)-2,4-Dimethylpent-2-enoyl Bromide (5b): This compound was prepared from (*E*)-2,4-dimethylpent-2-enoic acid (4b; 920 mg, 7.18 mmol) in a manner analogous to that specified for 5a and was also used without purification.

(*E*)-2,4,4-Trimethylpent-2-enoyl Bromide (5c): This compound was prepared from (*E*)-2,4,4-trimethylpent-2-enoic acid (4c;^[36] 1.20 g, 8.45 mmol) in a manner analogous to that specified for 5a and was also used without purification.

(*E*)-2-Methyl-3-phenylpropenoyl Bromide (5d): 1-Bromo-2-(dimethylamino)-2-methylpropene^[37] (1.00 M in CH₂Cl₂, 1.43 mL, 1.43 mmol, 1.0 equiv.) was added at 0 °C to a solution of α -methylcinnamic acid (211 mg, 1.30 mmol) in CH₂Cl₂ (1.5 mL). After warming to room temperature and stirring for 1 h, the solution was used directly for the preparation of 6d.

(E)-1-Diazo-3-ethylhex-3-en-2-one (6a): The crude acid bromide 5a was added at 0 °C to a solution of CH₂N₂ (0.37 M in diethyl ether, 84 mL, 31 mmol, 1.0 equiv.) and *i*Pr₂NEt (5.99 mL, 4.43 g, 34.3 mmol, 1.1 equiv.). The mixture was allowed to reach room temperature and stirred for 2 h. After filtration and evaporation in vacuo, the residue was purified by flash chromatography (petroleum ether/diethyl ether $20:1 \rightarrow 10:1$) to afford the title compound (1.334 g, 28% over two steps) as a yellow oil: ¹H NMR (500 MHz, CDCl₃): $\delta = 0.99$ (t, $J_{6,5} = 7.5$ Hz, 6-H₃)*, 1.05 (t, $J_{2',1'} = 7.5$ Hz, $2'-H_3$)*, 2.21 (dq, $J_{5,4} = J_{5,6} = 7.5$ Hz, 5-H₂), 2.32 (q, $J_{1',2'} = 7.5$ Hz, 1'-H₂), 5.54 (s, 1-H)**, 6.16 (t, $J_{4,5} = 7.4$ Hz, 4-H)** ppm; * = assignments interchangeable, ** = distinguishable by a C,H correlation spectrum. IR (film): $\tilde{v} = 3125, 3090, 2970, 2935, 2875, 2100,$ 1640, 1605, 1460, 1390, 1365, 1345, 1300, 1225, 1200, 1155, 1115, 1100, 1065 cm⁻¹. HRMS (EI = 70 eV) $C_8H_{12}N_2O$: calcd. 152.0950; found 152.0949.

(*E*)-1-Diazo-3,5-dimethylhex-3-en-2-one (6b): Compound 6b (126 mg, 83% over two steps) was prepared from crude 5b in a manner analogous to that specified for 6a: ¹H NMR (500 MHz, CDCl₃): $\delta = 1.02$ (d, $J_{5-Me,5} = J_{6,5} = 6.6$ Hz, 5-CH₃, 6-H₃), 1.83 (d, $J_{allyl} = 1.4$ Hz, 3-CH₃), 2.66 (dqq, $J_{5,4} = 9.4$, $J_{5,5-Me} = J_{5,6} = 6.7$ Hz, 5-H), 5.54 (s, 1-H), 6.07 (dq, $J_{4,5} = 9.4$, $J_{allyl} = 1.4$ Hz, 4-H) ppm. IR (film): $\tilde{v} = 3090$, 2965, 2930, 2870, 2360, 2335, 2105, 1740, 1700, 1645, 1605, 1560, 1540, 1515, 1460, 1395, 1345, 1245, 1155, 1060 cm⁻¹. HRMS (EI = 70 eV) C₈H₁₂N₂O: calcd. 152.0950; found 152.0949.

(*E*)-1-Diazo-3,5,5-trimethylhex-3-en-2-one (6c): Compound 6c (94 mg, 81% over two steps) was prepared from crude 5c in a manner analogous to that specified for 6a: ¹H NMR (500 MHz, CDCl₃): $\delta = 1.17$ (s, 2×5-CH₃, 6-H₃), 1.94 (d, $J_{allyl} = 1.4$ Hz, 3-CH₃), 5.52 (s, 1-H), 6.23 (q, $J_{allyl} = 1.4$ Hz, 4-H) ppm. IR (film): $\tilde{v} = 3090, 2960, 2910, 2870, 2100, 1735, 1635, 1610, 1465, 1405, 1360, 1345, 1230, 1185, 1145, 1100, 1060, 1030, 1005, 990, 925, 855, 720,$

700 cm⁻¹; elemental analysis calcd. (%) for $C_9H_{14}N_2O$ (166.2): C 65.03, H 8.49, N 16.85; found: C 64.95, H 8.27, N 16.59.

(*E*)-1-Diazo-3-methyl-4-phenylbut-3-en-2-one (6d):^[10b] This compound (127 mg, 52%) was prepared from a crude solution of 5d in a manner analogous to that specified for 6a: yellow solid (m.p. 85 °C). ¹H NMR (300 MHz, CDCl₃): $\delta = 2.11$ (d, $J_{allyl} = 1.3$ Hz, 3-CH₃), 5.70 (s, 1-H), 7.24 (incompletely resolved q, $J_{allyl} = 1.0$ Hz, 4-H), 7.29–7.45 (m, 5× Ar-H) ppm; elemental analysis calcd. (%) for C₁₁H₁₀N₂O (186.2): C 70.95, H 5.41, N 15.04; found C 70.73, H 5.69, N 14.78.

Methyl (*E***)-3-Ethylhex-3-enoate (7):** Under exclusion of light, a solution of silver(I) benzoate (400 mg, 1.75 mmol, 0.2 equiv.) in triethylamine (4 mL) was added dropwise to a solution of **6a** (1.334 g, 8.771 mmol) in methanol (15 mL). After the mixture had been stirred for 5 h at room temperature, the solvent was evaporated in vacuo and the residue was purified by flash chromatography (petroleum ether/diethyl ether 40:1) to afford the title compound (1.044 g, 76%) as a colorless liquid: ¹H NMR (300 MHz, CDCl₃): $\delta = 0.96$ (t, $J_{6,5} = J_{2',1'} = 7.5$ Hz, 6-H₃, 2'-H₃), 2.04 (dq, $J_{5,4} = J_{5,6} = 7.8$ Hz, 5-H₂), superimposed in part by 2.11 (q, $J_{1',2'} = 7.8$ Hz, 1'-H₂), 2.99 (br.s, 2-H₂), 3.67 (s, CO₂CH₃), 5.24 (t, $J_{4,5} = 7.2$ Hz, 4-H) ppm. IR (film): $\tilde{v} = 2965$, 2935, 2875, 1740, 1560, 1540, 1505, 1460, 1435, 1375, 1335, 1300, 1255, 1195, 1155, 1015 cm⁻¹. HRMS (EI = 70 eV) C₉H₁₆O₂: calcd. 156.1150; found 156.1146.

Methyl (*E***)-3,5-Dimethylhex-3-enoate (8):** This compound (497 mg, 77%) was prepared from **6b** in a manner analogous to that specified for 7: ¹H NMR (500 MHz, CDCl₃): $\delta = 0.93$ (d, $J_{5-Me,5} = J_{6,5} = 6.7$ Hz, 5-CH₃, 6-H₃), 1.67 (d, $J_{allyl} = 1.4$ Hz, 3-CH₃), 2.52 (dqq, $J_{5,4} = 9.1, J_{5,5-Me} = J_{5,6} = 6.7$ Hz, 5-H), 2.96 (m_c, 2-H₂), 3.67 (s, CO₂CH₃), 5.10 (dm_c, $J_{4,5} = 9.1$ Hz, 4-H) ppm. IR (film): $\tilde{v} = 2960$, 2870, 1745, 1465, 1435, 1415, 1390, 1360, 1335, 1300, 1260, 1225, 1190, 1160, 1040, 1005 cm⁻¹; elemental analysis calcd. (%) for C₉H₁₆O₂ (156.2): C 69.25, H 10.25; found: C 69.08, H 10.36.

Methyl (*E*)-3,5,5-Trimethylhex-3-enoate (9): This compound (637 mg, 87%) was prepared from 6c in a manner analogous to that specified for 7: ¹H NMR (500 MHz, CDCl₃): δ = 1.10 (s, 2×5-CH₃, 6-H₃), 1.78 (d, *J*_{allyl} = 1.4 Hz, 3-CH₃), 2.92 (d, *J*_{2,4} = 0.9 Hz, 2-H₂), 3.66 (s, CO₂CH₃), 5.28–5.29 (m, 4-H) ppm. IR (film): \tilde{v} = 2955, 2905, 2870, 1745, 1465, 1435, 1365, 1335, 1285, 1250, 1195, 1150, 1040, 1030, 1010, 890, 845, 820, 760, 710 cm⁻¹. HRMS (EI = 70 eV) C₁₀H₁₈O₂: calcd. 170.1307; found 170.1305.

Methyl (*E***)-3-Methyl-4-phenylbut-3-enoate (10):**^[10b] The title compound (102 mg, 86%) was prepared from **6d** in a manner analogous to that specified for 7: ¹H NMR (500 MHz, CDCl₃): $\delta = 1.94$ (d, $J_{allyl} = 1.4$ Hz, 3-CH₃), 3.19 (d, $J_{2,4} = 1.1$ Hz, 2-H₂), 3.72 (s, CO₂CH₃), 6.39 (br.s, 4-H), 7.19–7.23 and 7.24–7.27 (C₆H₅) ppm; elemental analysis calcd. (%) for C₁₂H₁₄O₂ (190.2): C 75.76, H 7.42; found: C 75.52, H 7.51.

Compounds (*E***)- and (***Z***)-11, -12, -13, and -14:** These compounds were synthesized as described in ref.^[8]

Methyl (E)-4,8-Dimethylnona-3,7-dienoate [(E)-18]:^[16] (Trimethylsilyl)diazomethane (2.0 m in hexane, 0.83 mL, 1.66 mmol, 1.3 equiv.) was added to a solution of (*E*)-4,8-dimethylnona-3,7dienoic acid [(*E*)-**17**;^[16] 235 mg, 1.28 mmol] in methanol (2.5 mL) and benzene (9 mL). After the mixture had been stirred for 1 h, the solvent was evaporated in vacuo and the residue was purified by flash chromatography (cyclohexane/EtOAc, 50:1) to afford the title compound (240 mg, 96%) as a colorless liquid: ¹H NMR (300 MHz, CDCl₃): δ = 1.60, 1.63, and 1.68 (3×s, 4-CH₃, 8-CH₃, 9-H₃), 2.01–2.11 (m, 5-H₂, 6-H₂), 3.05 (br. d, $J_{2,3}$ = 7.2 Hz, 2-H₂), 3.68 (s, CO₂CH₃), 5.09 (m_c, 7-H), 5.33 (br. t, $J_{3,2} = 7.5$ Hz, 3-H) ppm.

Methyl (Z)-4,8-Dimethylnona-3,7-dienoate [(Z)-18]:^[16] This compound (244 mg, 96%) was prepared from (Z)-17^[16] (239 mg, 1.30 mmol) in a manner analogous to that specified for (*E*)-18: ¹H NMR (300 MHz, CDCl₃): δ = 1.61, 1.68, and 1.74 (3×s, 4-CH₃, 8-CH₃, 9-H₃), 2.04 (m_c, 5-H₂, 6-H₂), 3.04 (dm_c, *J*_{2,3} = 7.2 Hz, 2-H₂), 3.67 (s, CO₂CH₃), 5.06–5.12 (m, 7-H), 5.32 (tm_c, *J*_{3,2} = 7.5 Hz, 3-H) ppm.

Methyl Cyclopentylideneacetate [(22),^[19] 90:10 Mixture with Methyl (Cyclopent-1-enyl)acetate (24)]: Methyl (dimethoxyphosphonyl)acetate (21,^[21] 10.0 mL, 11.3 g, 61.8 mmol, 1.0 equiv.) was added to NaH (1.78 g, 74.1 mmol, 1.2 equiv.) in methanol (48 mL). After the mixture had been stirred for 40 min, cyclopentanone (5.47 mL, 5.20 g, 61.8 mmol) was added and the mixture was stirred overnight. Aq. NH₄Cl (100 mL) was added and the mixture was extracted with EtOAc (4×100 mL). The combined organic extracts were dried with MgSO₄ and the solvents were evaporated in vacuo. The residue was purified by vacuum distillation (140-145 °C/ 2.0 kPa) to afford a 90:10 mixture of 22/24 (8.06 g, 93%) as a colorless liquid: ¹H NMR (300 MHz, CDCl₃): δ = 1.66 (dddd, $J_{4',3'-H(1)}$ = $J_{4',3'-H(2)} = J_{4',5'-H(1)} = J_{4',5'-H(2)} = 6.8$ Hz, 4'-H₂; 22), 1.76 (dddd, $J_{3',2'-H(1)} = J_{3',2'-H(2)} = J_{3',4'-H(1)} = J_{3',4'-H(2)} = 6.8$ Hz, 3'-H₂; 22), 1.85–1.95 (m, 4'-H₂; 24), 2.31–2.37 (m, 3'-H₂, 5'-H₂; 24), 2.44 (br. t, $J_{5',4'-H(1)} = J_{5',4'-H(2)} = 7.0$ Hz, 5'-H₂, **22**), 2.78 (tm_c, $J_{2',3'-H(1)} = J_{2',3'-H(2)} = 6.7$ Hz, 2'-H₂; **22**), 3.13 (br. s, 2-H₂; **24**), 3.69 (s, CO₂CH₃; **22**, **24**), 5.54 (m_c, 2'-H; **24**), 5.81 (m_c, 2-H; **22**) ppm.

Methyl Cyclohexylideneacetate (23):^[20] The title compound (6.114 g, 98%) was prepared from cyclohexanone (4.20 mL, 3.97 g, 40.5 mmol) in a manner analogous to that specified for 22, but the purification was carried out by flash chromatography (cyclohexane/EtOAc, 8:1): ¹H NMR (500 MHz, CDCl₃): $\delta = 1.56-1.67$ (m, 3'-H₂, 4'-H₂, 5'-H₂), 2.19 (br. t, $J_{6',5'-H(1)} = J_{6',5'-H(2)} = 6.2$ Hz, 6'-H₂)*, 2.82 (br. t, $J_{2',3'-H(1)} = J_{2',3'-H(2)} = 5.8$ Hz, 2'-H₂)*, 3.68 (s, CO₂CH₃), 5.60 (m_c, 2-H) ppm; * = assignments interchangeable.

Methyl (Cyclopent-1-enyl)acetate (24):^[19] *n*-BuLi (2.6 м in hexane, 6.47 mL, 16.8 mmol, 1.1 equiv.) was added at -78 °C to a solution of diisopropylamine (2.61 mL, 1.87 g, 18.5 mmol, 1.2 equiv.) in THF (16 mL). After the mixture had been stirred for 1 h, a solution of 22 (2.14 g, 15.3 mmol; 90:10 mixture with 24) in THF (7 mL) was added and the mixture was stirred for 1 h. Aq. NH₄Cl (10 mL) was added and the mixture was allowed to reach room temperature. After extraction with EtOAc (4×40 mL), the combined organic extracts were washed with aq. NaCl (2×40 mL) and dried with MgSO₄. Evaporation in vacuo followed by flash chromatography (cyclohexane/EtOAc, 50:1) afforded the title compound (1.637 g, 76%): ¹H NMR (300 MHz, CDCl₃): *δ* = 1.90 (dddd, *J*_{4',3'-H(1)} = *J*_{4',3'-H(2)} = *J*_{4',5'-H(2)} = 7.5 Hz, 4'-H₂), 2.33 (m_c, 3'-H₂, 5'-H₂), 3.13 (br.s, 2-H₂), 3.69 (s, CO₂Me), 5.54 (m_c, 2'-H) ppm.

Methyl (Cyclohex-1-enyl)acetate (25):^[20] *n*-BuLi (2.07 M in hexane, 18.8 mL, 38.9 mmol, 1.05 equiv.) was added at -78 °C to a solution of diisopropylamine (5.50 mL, 3.94 g, 38.9 mmol, 1.05 equiv.) in THF (40 mL). After the mixture had been stirred for 1 h, a solution of **23** (5.71 g, 37.0 mmol) in THF (50 mL) was added and the mixture was stirred for a further 1 h. HOAc (6.4 mL, 6.7 g, 0.11 mol, 3.0 equiv.) was added and the mixture was stirred for 15 min. After addition of KHSO₄ (1.0 M in H₂O, 62 mL) the mixture was allowed to reach room temperature. After extraction with EtOAc (3×100 mL) the combined organic extracts were washed with aq. NaHCO₃ (2×50 mL) and aq. NaCl (50 mL) and dried with MgSO₄. Evaporation in vacuo and vacuum distillation (98–102 °C/

3.0 kPa) afforded the title compound (4.443 g, 78%): ¹H NMR (300 MHz, CDCl₃): δ = 1.53–1.68 (m, 4'-H₂, 5'-H₂), 2.00–2.05 (m, 3'-H₂, 6'-H₂), 2.95 (br.s, 2-H₂), 3.68 (s, CO₂CH₃), 5.56 (m_c, 2'-H) ppm.

Dimethyl (*E*)-2-(3-Methylbutylidene)succinoate [(*E*)-31,^[38] 81:19 Mixture with (*Z*)-31]: A solution of (*E*)-32 (500 mg, 2.06 mmol, *E:Z* = 82:18) in methanol (5 mL) was added to NaH (99 mg, 4.1 mmol, 2.0 equiv.) in methanol (5 mL). After the mixture had been stirred for 2 d at room temperature, aq. NH₄Cl (10 mL) was added. The mixture was extracted with EtOAc (5 × 20 mL) and the combined organic extracts were dried with MgSO₄. After evaporation in vacuo, the residue was purified by flash chromatography (cyclohexane/EtOAc, 20:1 → 15:1) to afford **31** (386 mg, 87%, *E:Z* = 81:19). Isomerically pure (*E*)-**31** for the next step could be obtained by more meticulously performed flash chromatography: ¹H NMR (300 MHz, CDCl₃): $\delta = 1.77$ (qqt, $J_{3',3'-Me} = J_{3',4'} = J_{3',2'} = 6.7$ Hz, 3'-H), 2.07 (t, $J_{2',1'} = J_{2',3'} = 7.3$ Hz, 2'-H₂), 3.35 (s, 3-H₂), 3.67 (s, ⁴CO₂CH₃)*, 3.74 (s, ¹CO₂CH₃)*, 6.99 (t, $J_{1',2'} = 7.6$ Hz, 1'-H) ppm; * = interchangeable.

Dimethyl (Z)-2-(3-Methylbutylidene)succinoate [(Z)-31,^[39] 80:20 Mixture with (E)-31]: A solution of 37 (2.00 g, 5.30 mmol) in THF (10 mL) was added at 0 °C to a suspension of NaH (127 mg, 5.29 mmol, 1.0 equiv.) in THF (10 mL). The mixture was allowed to reach room temperature and stirred for 30 min. After the mixture had been cooled to 0 °C, a solution of isovaleraldehyde (29; 456 mg, 5.30 mmol, 1.0 equiv.) in THF (10 mL) was added. The mixture was allowed to reach room temperature and stirred for 3 h. After addition of aq. NH₄Cl (55 mL), the mixture was extracted with EtOAc $(4 \times 50 \text{ mL})$ and dried with MgSO₄. Evaporation in vacuo and flash chromatography (cyclohexane/EtOAc, 25:1) afforded **31** (977 mg, 86%, Z:E = 80:20). Isometically pure (Z)-**31** for the next step could be obtained by more meticulously performed flash chromatography: ¹H NMR (300 MHz, CDCl₃): δ = 0.93 (d, $J_{3'-Me,3'} = J_{4',3'} = 6.6$ Hz, 3'-CH₃, 4'-H₃), 1.72 (qqt, $J_{3',3'-Me} = J_{3',4'} = J_{3',2'} = 6.7$ Hz, 3'-H), 2.47 (br. t, $J_{2',1'} = J_{2',3'} =$ 7.2 Hz, 2'-H₂), 3.68 and 3.73 (2×s, 2×CO₂CH₃), 6.08 (br.t, $J_{1',2'} = 7.5$ Hz, 1'-H) ppm.

Diethyl (E)-2-(3-Methylbutylidene)succinoate [(E)-32,^[40] 82:18 Mixture with (Z)-32]: NaH (168 mg, 7.00 mmol, 1.0 equiv.) was added at 0 °C to a solution of diethyl phosphite (26; 967 mg, 7.00 mmol) in EtOH (35 mL). The mixture was allowed to reach room temperature and stirred for 30 min. After addition of diethyl maleate (27, 1.21 g, 7.00 mmol, 1.0 equiv.) stirring was continued for 1 h. Isovaleraldehyde (29; 603 mg, 7.00 mmol, 1.0 equiv.) was added and the mixture was stirred for 4 h. After addition of aq. NH₄Cl (25 mL), the mixture was extracted with EtOAc (4×30 mL). The combined organic extracts were dried with MgSO₄. After evaporation in vacuo the residue was purified by flash chromatography (cyclohexane/EtOAc, $15:1 \rightarrow 10:1$) to afford **32** (1.034 g, 61%, E:Z= 82:18): ¹H NMR (300 MHz, CDCl₃): δ = 0.93 (d, J_{vic} = 6.7 Hz, 3'-CH₃, 4'-H₃), 1.24 (t, J_{vic} = 7.2 Hz, ⁴CO₂CH₂CH₃)*, 1.28 (t, J_{vic} = 7.1 Hz, ${}^{1}CO_{2}CH_{2}CH_{3}$, 1.72 [qqt, $J_{3',3'-Me} = J_{3',4'} = J_{3',2'}$ 6.8 Hz, 3'-H; (Z)-32], superimposed in part by 1.78 [qqt, $J_{3',3'-Me}$ = $J_{3',4'}$ = $J_{3',2'}$ = 6.6 Hz, 3'-H; (E)-32], 2.08 [t, $J_{2',1'}$ = $J_{2',3'}$ = 7.3 Hz, 2'-H₂; (*E*)-**32**], 2.47 [t, $J_{2',1'} = J_{2',3'} = 7.3$ Hz, 2'-H₂; (*Z*)-32], 3.26 [br.s, 3-H₂; (Z)-32], 3.33 [br.s, 3-H₂; (E)-32], 4.15 (q, J_{vic} 7.0 Hz, ${}^{4}\text{CO}_{2}\text{CH}_{2}\text{CH}_{3}$)**, 4.20 (q, J_{vic} = 7.0 Hz, ${}^{1}\text{CO}_{2}\text{CH}_{2}\text{CH}_{3}$ **, 6.06 [t, $J_{1',2'}$ = 7.5 Hz, 1'-H; (Z)-32], 6.97 [t, $J_{1',2'}$ = 7.7 Hz, 1'-H; (E)-32] ppm; *** = interchangeable; elemental analysis calcd. (%) for C13H22O4 (242.3): C 64.45, H 9.15; found: C 64.65, H 9.29.

Dimethyl (*E***)-2-Benzylidenesuccinoate [(***E***)-33**,^[41] **92:8 Mixture with** (*Z***)-33]:** A solution of (*E*)-**34** (1.92 g, 7.33 mmol, E:Z = 92:8) in

2127

methanol (20 mL) was added to NaH (352 mg, 14.7 mmol, 2.0 equiv.) in methanol (70 mL). After the mixture had been stirred for 3 d at room temperature, aq. NH₄Cl (50 mL) was added. The mixture was extracted with EtOAc (4×50 mL) and the combined organic extracts were dried with MgSO₄. After evaporation in vacuo, the residue was purified by flash chromatography (cyclohexane/EtOAc, 5:1 \rightarrow 3:1) to afford **33** (1.383 g, 81%, *E:Z* = 92:8). Isomerically pure (*E*)-**33** for the next step could be obtained by more meticulously performed flash chromatography: ¹H NMR (300 MHz, CDCl₃): δ = 3.54 (s, 3-H₂), 3.73 and 3.83 (2×s, 2×CO₂CH₃), 7.33–7.43 (m, C₆H₅), 7.90 (s, 1'-H) ppm.

Dimethyl (Z)-2-Benzylidenesuccinoate [(Z)-33,^[42] **67:33 Mixture with (E)-33]:** The title compound (795 mg, 48%, *Z*:*E* = 67:33) was prepared from benzaldehyde (**30**; 757 mg, 7.13 mmol, 1.0 equiv.) in a manner analogous to that specified for (*Z*)-**31**. Isomerically pure (*Z*)-**33** for the next step could be obtained by more meticulously performed flash chromatography: ¹H NMR (300 MHz, CDCl₃): δ = 3.48 (s, 3-H₂), 3.64 and 3.72 (2 s, 2 CO₂CH₃), 6.88 (s, 1'-H), 7.26–7.35 (m, C₆H₅) ppm.

Diethyl (E)-2-Benzylidenesuccinate [(E)-34,^[43] 93:7 Mixture with (Z) -34]: NaH (42 mg, 1.8 mmol, 1.0 equiv.) was added at 0 °C to a solution of diethyl phosphite (26; 242 mg, 1.75 mmol) in EtOH (9 mL). The mixture was allowed to reach room temperature and stirred for 30 min. After addition of diethyl maleate (27; 301 mg, 1.75 mmol, 1.0 equiv.) stirring was continued for 3 h. Benzaldehyde (30; 0.18 mL, 0.19 g, 1.75 mmol, 1.0 equiv.) was added and the mixture was stirred overnight. After addition of aq. NH₄Cl (20 mL), the mixture was extracted with EtOAc (4×20 mL). The combined organic extracts were dried with MgSO₄. After evaporation in vacuo the residue was purified by flash chromatography (cyclohexane/EtOAc, 15:1) to afford **34** (220 mg, 48%, E:Z = 93:7). Isomerically pure (E)-34 for the next step could be obtained by more meticulously performed flash chromatography: ¹H NMR (300 MHz, CDCl₃): δ = 1.27 (t, J_{vic} = 7.2 Hz, ${}^{4}CO_{2}CH_{2}CH_{3}$)*, 1.34 (t, J_{vic} = 7.1 Hz, ${}^{1}CO_{2}CH_{2}CH_{3}$)*, 3.53 (s, 3-H₂), 4.19 (q, J_{vic} = 7.1 Hz, ${}^{4}\text{CO}_{2}\text{CH}_{2}\text{CH}_{3}$)**, 4.28 (q, J_{vic} = 7.1 Hz, ${}^{1}\text{CO}_{2}\text{CH}_{2}\text{CH}_{3}$)**, 7.30– 7.43 (m_c, C₆H₅), 7.89 (s, 1'-H) ppm; *, ** = interchangeable.

Diethyl (*Z*)-2-Benzylidenesuccinoate [(*Z*)-34,^[43] 81:19 Mixture with (*E*)-34]: The title compound (207 mg, 79%, *Z*:*E* = 81:19) was prepared from $38^{[22]}$ (406 mg, 1.00 mmol) and benzaldehyde (30; 106 mg, 1.00 mmol, 1.0 equiv.) in a manner analogous to that specified for (*Z*)-31 but with stirring for only 1 h after the addition of the aldehyde. Isomerically pure (*Z*)-34 for the next step could be obtained by more meticulously performed flash chromatography: ¹H NMR (500 MHz, CDCl₃): δ = 1.09 (t, J_{vic} = 7.1 Hz, ¹CO₂CH₂CH₃)*, 1.27 (t, J_{vic} = 7.2 Hz, ⁴CO₂CH₂CH₃)*, 3.46 (d, $J_{3,1'}$ = 1.2 Hz, 3-H₂), 4.11 (q, J_{vic} = 7.2 Hz, ⁴CO₂CH₂CH₃)**, 4.18 (q, J_{vic} = 7.1 Hz, ¹CO₂CH₂CH₃)**, 6.88 (br. s, 1'-H), 7.27–7.33 (m, C₆H₅) ppm; *, ** = interchangeable.

Dimethyl 2-(Diphenoxyphosphonyl)succinate (37): Diphenyl phosphite (**35**; 3.83 mL, 4.68 g, 20.0 mmol) was added at 0 °C to a suspension of NaH (480 mg, 20.0 mmol, 1.0 equiv.) in THF (20 mL). The mixture was allowed to reach room temperature and stirred for 30 min. Dimethyl maleate (**36**, 2.50 mL, 2.88 g, 20.0 mmol, 1.0 equiv.) was added and the mixture was stirred for 3 h. After addition of H₂O (10 mL), the mixture was extracted with EtOAc (4×25 mL) and dried with MgSO₄. After evaporation in vacuo, the residue was purified by flash chromatography (cyclohexane/EtOAc, 7:1) to afford the title compound (5.184 g, 69%): ¹H NMR (300 MHz, CDCl₃): δ = AB signal (δ_A = 3.03, δ_B = 3.27, J_{AB} = 17.5, A part additionally split by $J_{B,31P}$ = 10.0, $J_{A,2}$ = 3.4, B part additionally split by $J_{B,2}$ = 11.4, $J_{B,31P}$ = 7.7 Hz, 3-H₂), 3.71 (s,

CO₂CH₃), 3.82 (ddd, $J_{2,^{31}P} = 24.8$, $J_{2,3-H(B)} = 11.4$, $J_{2,3-H(A)} = 3.4$ Hz, 2-H), superimposed by 3.81 (s, CO₂CH₃), 7.16–7.21 and 7.30–7.35 (2 m, 2 Ph) ppm. IR (film): $\tilde{v} = 3070$, 3005, 2955, 1740, 1590, 1490, 1455, 1440, 1410, 1365, 1325, 1280, 1210, 1185, 1160, 1070, 1025, 1010, 945, 905, 860, 840, 770, 690 cm⁻¹; elemental analysis calcd. (%) for C₁₈H₁₉O₇P (378.3): C 57.16, H 5.06; found: C 57.00, H 5.28.

(4S,5S)-4,5-Diethyl-4-hydroxy-4,5-dihydro-3*H*-furan-2-one (39a): (DHQ)₂PHAL (78 mg, 0.10 mmol, 10 mol-%), K₃Fe(CN)₆ (988 mg, 3.00 mmol, 3.0 equiv.), K₂CO₂ (415 mg, 3.00 mmol, 3.0 equiv.), $MeSO_2NH_2$ (95 mg, 1.0 mmol, 1.0 equiv.), and K_2O $sO_2(OH)_4$ (7.4 mg, 20 µmol, 2 mol-%) were dissolved in tBuOH (5 mL) and H₂O (5 mL). After the mixture had been cooled to 0 °C, 7 (156 mg, 1.00 mmol) was added. After the mixture had been stirred overnight at 0 °C, aq. Na₂SO₃ (5 mL) was added, the mixture was stirred for 1 h at room temperature and extracted with EtOAc (4×20 mL), and the combined organic extracts were dried with MgSO₄. After evaporation in vacuo the residue was purified by flash chromatography (cyclohexane/EtOAc, 2:1) to afford the title compound (103 mg, 65%): $[a]_{D} = -69.6$ (c = 0.3 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 1.01$ (t, $J_{2',1'} = 7.5$ Hz, 2'-H₃)*, 1.09 (t, $J_{2'',1''}$ = 7.4 Hz, 2''-H₃)*, AB signal (δ_A = 1.61, δ_B = 1.73, J_{AB} = 14.8, A part additionally split by $J_{A,2'}$ = 7.2, B part additionally split by $J_{B,2'}$ = 7.2 Hz, 1'-H₂), superimposed by AB signal (δ_A = 1.67, $\delta_{\rm B}$ = 1.79, $J_{\rm AB}$ = 14.6, A part additionally split by $J_{{\rm A},2^{\prime\prime}}$ = 7.1, $J_{A,5}$ = 3.2, B part additionally split by $J_{B,5}$ = 9.8, $J_{B,2''}$ = 7.3 Hz, 1''-H₂), 2.12 (br.s, 4-OH), AB signal ($\delta_A = 2.54$, $\delta_B = 2.60$, $J_{AB} = 17.5 \text{ Hz}, 3-\text{H}_2$, 4.11 (dd, $J_{5,1''-\text{H}(B)} = 9.8, J_{5,1''-\text{H}(A)} = 3.2 \text{ Hz}$, 5-H) ppm; * = interchangeable. IR (film): $\tilde{v} = 3445, 2975, 2940,$ 2885, 1780, 1770, 1760, 1755, 1465, 1405, 1380, 1355, 1310, 1265, 1230, 1170, 1140, 1120, 1085, 1050, 1020, 1000, 970, 935, 825 cm⁻¹; $t_r(4S,5S) = 29.96 \text{ min}, t_r(4R,5R) = 25.79 \text{ min} (n-heptane/propan-2$ ol, 96:4); 68% ee; elemental analysis calcd. (%) for $C_8H_{14}O_3$ (158.2): C 60.74, H 8.92; found: C 60.94, H 9.12.

(4*R*,5*R*)-4,5-Diethyl-4-hydroxy-4,5-dihydro-3*H*-furan-2-one (39b): This compound (74 mg, 84%) was prepared from 7 (87 mg, 0.56 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: $[a]_D = +72.2$ (c = 0.5 in CHCl₃); $t_r(4R,5R) = 25.28$ min, $t_r(4S,5S) = 29.37$ min (*n*-heptane/propan-2-ol, 96:4); 72% *ee*.

Methyl [(15,25)-1,2-Dihydroxycyclopentyl]acetate (40a): This compound (968 mg, 87%) was prepared from 24 (894 mg, 6.38 mmol) in a manner analogous to that specified for 39a: $[a]_{D} = +1.8$ (c = 0.6 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ = 1.49 (ddddd, J_{gem} = 12.4, $J_{4'-H(1),5'-H(1)}$ = 9.1, $J_{4'-H(1),5'-H(2)}$ = 8.9, $J_{4'-H(1),3'-H(1)}$ = 6.9, $J_{4'-H(1),3'-H(2)} = 4.7$ Hz, 4'-H¹), 1.60 (ddd, $J_{gem} = 13.3$, $J_{5'-H(1),4'-H(1)}$ = 9.3, $J_{5'-H(1), 4'-H(2)}$ = 6.7 Hz, 5'-H¹), 1.69 (dddd, J_{gem} = 13.1, $J_{3'-H(1), 4'-H(2)} = 9.7, J_{3'-H(1),4'-H(1)} = J_{3'-H(1),2'} = 7.0 \text{ Hz}, \overline{3'-H^1}, 1.82$ (ddddd, $J_{gem} = 12.3, J_{4'-H(2),3'-H(1)} = 9.6, J_{4'-H(2),3'-H(2)} = 9.2,$ $J_{4'-H(2),5'-H(1)} = 6.7, J_{4'-H(2),5'-H(2)} = 4.7 \text{ Hz}, 4'-H^2), 1.91 \text{ (ddd, } J_{gem}$ = 13.3, $J_{5'-H(2),4'-H(1)}$ = 8.8, $J_{5'-H(2),4'-H(2)}$ = 4.5 Hz, 5'-H²), 1.99 (dddd, $J_{gem} = 13.0, J_{3'-H(2),4'-H(2)} = 8.4, J_{3'-H(2),2'} = 7.8, J_{3'-H(2),4'-H(1)}$ = 4.6 Hz, 3'-H²), AB signal (δ_A = 2.56, δ_B = 2.65, J_{AB} = 15.9 Hz, 2- H_2), 3.16 (m_c, 2'-OH), 3.57 (s, 1'-OH), 3.71 (s, CO_2CH_3), 3.86 (ddd, $J_{2',3'-H(1)} = J_{2',3'-H(2)} = 7.5, J_{2',2'-OH} = 5.4 \text{ Hz}, 2'-H) \text{ ppm. IR (film):}$ $\tilde{v} = 3440, 2955, 2875, 1730, 1440, 1410, 1340, 1285, 1255, 1205,$ 1170, 1105, 1050, 1010, 975, 920, 855, 785, 725, 665, 585, 555 cm⁻¹.

The enantiomeric excess of **40a** was determined after transformation into its acetonide by the following procedure: pTsOH·H₂O (cat.) was added to a solution of **40a** (159 mg, 0.913 mmol) in 2,2dimethoxypropane (10 mL). After the mixture had been stirred for 12 h, aq. NaHCO₃ (15 mL) was added. The mixture was extracted with EtOAc (4×50 mL) and dried with MgSO₄. After evaporation in vacuo the residue was purified by flash chromatography (cyclohexane/EtOAc, 5:1) to afford the acetonide (= methyl {2,2-dimethyl-4,5,6,6a-tetrahydro-2*H*-cyclopent[1,3]dioxolan-3a-yl}-acetate) of compound **40a** (177 mg, 90%).



 $[a]_{\rm D}$ = +5.4 (*c* = 0.9 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ = 1.35 and 1.43 (2 s, 2× 2′′-CH₃), 1.53–1.66 and 1.79–1.97 (2 m, 3′-H₂, 4′-H₂, 5′-H₂), AB signal ($\delta_{\rm A}$ = 2.74, $\delta_{\rm B}$ = 2.87, $J_{\rm AB}$ = 14.9 Hz, 2-H₂), 3.69 (s, CO₂CH₃), 4.54 (dm_c, $J_{2',3'-H(1)}$ = 4.5 Hz, 2′-H) ppm. IR (film): \tilde{v} = 2985, 2960, 2940, 2880, 2850, 1740, 1460, 1440, 1380, 1370, 1350, 1305, 1290, 1250, 1210, 1175, 1140, 1100, 1045, 1010, 910, 885, 810, 515 cm⁻¹; $t_{\rm r}$ (1′*S*,2′*S*) = 53.75 min, $t_{\rm r}$ (1′*R*,2′*R*) = 52.38 min (85 °C, 130 kPa); 66% *ee*; elemental analysis calcd. (%) for C₁₁H₁₈O₄ (214.3): C 61.66, H 8.47; found: C 61.62, H 8.34.

Methyl [(1*R*,2*R*)-1,2-Dihydroxycyclopentyl]acetate (40b): This compound (414 mg, 83%) was prepared from 24 (400 mg, 2.85 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: $[a]_D = -2.9$ (c = 1.4 in CHCl₃); elemental analysis calcd. (%) for C₈H₁₄O₄ (174.2): C 55.16, H 8.10; found: C 55.08, H 8.15.

The enantiomeric excess was determined after transformation of **40b** (150 mg, 0.861 mmol) into its acetonide (174 mg, 94%) by a procedure analogous to that described for **40a**: $[a]_D = -5.6$ (c = 1.0 in CHCl₃); $t_r(1'R,2'R) = 52.25$ min, $t_r(1'S,2'S) = 53.79$ min (85 °C, 130 kPa); 79% *ee.*

(3a*S*,7a*S*)-3a-Hydroxy-3a,4,5,6,7,7a-hexahydrobenzo4,5dihydro-3*H*-furan-2-one (41a),^[44] as a 24:76 Mixture with [(1*S*,2*S*)-1,2-Dihydroxycyclohexyl]acetate (42a): A mixture (135 mg) of the title compounds (41a: 28 mg, 18%; 42a: 107 mg, 59%) was prepared from 25 (150 mg, 0.973 mmol) in a manner analogous to that specified for 39a: 41a: $[a]_D = -27.4$ (c = 1.0 in CHCl₃); t_r (3a*S*,7a*S*) = 53.66 min, t_r (3a*R*,7a*R*) = 53.79 min (120 °C, 100 kPa); 23% ee; elemental analysis calcd. (%) for C₈H₁₂O₃ (156.2): C 61.52, H 7.74; found: C 61.48, H 7.83.

(3a *R*, 7a *R*)-3a-Hydroxy-3a, 4, 5, 6, 7, 7a-hex ahydrobenzo4, 5dihydro-3*H*-furan-2-one (41b), as a 27:73 Mixture with [(1*R*,2*R*)-1,2-Dihydroxycyclohexyl]acetate (42b): A mixture (150 mg) of the title compounds (41b: 35 mg, 23%; 42b: 115 mg, 62%) was prepared from 25 (150 mg, 0.973 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: 41b: [*a*]_D = +40.2 (*c* = 0.8 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ = 1.32–1.42 and 1.52–1.76 and 1.86–2.01 (3 m, 4-H₂, 5-H₂, 6-H₂, 7-H₂), 2.12 (m_c, 3a-OH), AB signal (δ_A = 2.51, δ_B = 2.54, J_{AB} = 16.4 Hz, 3-H₂), 4.01 (dd, $J_{7a,7-H(1)}$ = 11.4, $J_{7a,7-H(2)}$ = 5.0 Hz, 7a-H) ppm; *t*_r(3a-*R*,7a*R*) = 51.12 min, *t*_r(3a*S*,7a*S*) = 53.14 min (120 °C, 100 kPa); 44% *ee*.

(4*S*,5*S*)-4-Hydroxy-5-isopropyl-4-methyl-4,5-dihydro-3*H*-furan-2one (43a): This compound (138 mg, 87%) was prepared from 8 (156 mg, 1.00 mmol) in a manner analogous to that specified for 39a: colorless solid (m.p. 47 °C). $[a]_{\rm D} = -50.7$ (c = 0.8 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 1.05$ (d, $J_{1'-{\rm Me},1'} = 6.8$ Hz, 1'-CH₃)*, 1.10 (d, $J_{2',1'} = 6.6$ Hz, 2'-H₃)*, 1.50 (s, 4-CH₃), 2.16 (dqq, $J_{1',5} = 8.6$, $J_{1',1'-{\rm Me}} = J_{1',2'} = 6.7$ Hz, 1'-H), 2.23 (br. s, 4-OH), AB signal ($\delta_{\rm A} = 2.62$, $\delta_{\rm B} = 2.65$, $J_{\rm AB} = 17.5$ Hz, 3-H₂), 3.85 (d, $J_{5,1'} =$ 8.6 Hz, 5-H) ppm; * = interchangeable. IR (film): $\tilde{v} = 3450$, 2965, 2935, 2880, 1765, 1745, 1480, 1465, 1390, 1370, 1340, 1275, 1240, 1170, 1145, 1120, 1110, 1095, 1010, 985, 950, 810 cm⁻¹; $t_r(4S,5S) = 55.98 \text{ min}, t_r(4R,5R) = 55.23 \text{ min}$ (90 °C, 30 min, 2 °C/min, 140 °C, 100 kPa); 58% *ee*.

(4*R*,5*R*)-4-Hydroxy-5-isopropyl-4-methyl-4,5-dihydro-3*H*-furan-2one (43b): This compound (104 mg, 66%) was prepared from 8 (156 mg, 1.00 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: $[a]_D = +51.1$ (c = 0.4 in CHCl₃); $t_r(4R,5R) = 5.75$ min, $t_r(4S,5S) = 6.14$ min (85 °C, 130 kPa); 69% *ee*; elemental analysis calcd. (%) for C₈H₁₄O₃ (158.1): C 60.74, H 8.92; found: C 60.81, H 9.00.

(4*S*,5*S*)-5-*tert*-Butyl-4-hydroxy-4-methyl-4,5-dihydro-3*H*-furan-2one (44a): This compound (95 mg, 55%) was prepared from 9 (170 mg, 1.00 mmol) in a manner analogous to that specified for 39a: $[a]_{\rm D} = -21.6$ (c = 1.0 in CHCl₃); $t_{\rm r}(4S,5S) = 18.43$ min, $t_{\rm r}(4R,5R) = 23.46$ min (*n*-heptane/propan-2-ol, 95:5); 59% *ee*.

(4*R*,5*R*)-5-*tert*-Butyl-4-hydroxy-4-methyl-4,5-dihydro-3*H*-furan-2one (44b): This compound (96 mg, 56%) was prepared from 9 (170 mg, 1.00 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: colorless solid (m.p. 86 °C). [*a*]_D = +23.2 (*c* = 1.2 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ = 1.13 (s, 2× 1'-CH₃, 2'-H₃), 1.55 (s, 4-CH₃), AB signal (δ_A = 2.61, δ_B = 2.65, J_{AB} = 17.5 Hz, 3-H₂), 3.90 (s, 5-H) ppm. IR (film): \tilde{v} = 3605, 3445, 3035, 3000, 2965, 2910, 2875, 1770, 1485, 1470, 1410, 1400, 1385, 1365, 1330, 1245, 1195, 1155, 1110, 1040, 1005, 940 cm⁻¹; $t_r(4R,5R)$ = 22.65 min, $t_r(4S,5S)$ = 18.51 min (*n*-heptane/propan-2-ol, 95:5); 65% *ee*; elemental analysis calcd. (%) for C₉H₁₆O₃ (172.1): C 62.77, H 9.36; found: C 62.54, H 9.37.

(45,55)-4-Hydroxy-4-methyl-5-phenyl-4,5-dihydro-3*H*-furan-2-one (45a): This compound (52 mg, 75%) was prepared from 10 (69 mg, 0.36 mmol) in a manner analogous to that specified for **39a**: $[a]_D$ = +10.1 (c = 0.8 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ = 1.22 (d, ⁴ $J_{4-OH,3-H(A)}$ = 2.0 Hz, 4-OH), 1.45 (s, 4-CH₃), AB signal (δ_A = 2.71, δ_B = 2.78, J_{AB} = 17.1, A part additionally split by $J_{A,4-OH}$ = 2.0 Hz, 3-H₂), 5.26 (s, 5-H), 7.36–7.46 (m, C₆H₅) ppm. IR (KBr): \tilde{v} = 3520, 3455, 3065, 3035, 2975, 2935, 1790, 1780, 1770, 1760, 1755, 1500, 1455, 1385, 1275, 1235, 1200, 1105, 1015, 955, 945, 910, 875, 820, 750, 700 cm⁻¹; $t_r(4S,5S)$ = 24.91 min, $t_r(4R,5R)$ = 22.22 min (150 °C, 100 kPa); 83% *ee.*

(4*R*,5*R*)-4-Hydroxy-4-methyl-5-phenyl-4,5-dihydro-3*H*-furan-2-one (45b): This compound (28 mg, 69%) was prepared from 10 (40 mg, 0.21 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: colorless solid (m.p. 106 °C). $[a]_{\rm D} = -10.8 \ (c = 1.0 \ \text{in CHCl}_3); \ t_r(4R,5R) = 21.66 \ \text{min}, \ t_r(4S,5S) = 24.82 \ \text{min} \ (150 \ ^{\circ}\text{C}, \ 100 \ \text{kPa}); \ 85\% \ ee; \ \text{elemental analysis calcd.}$ (%) for C₁₁H₁₂O₃ (192.2): C 68.75, H 6.29; found: C 68.65, H 6.41.

(4*S*,5*S*)-4-Hydroxy-5-isobutyl-4-methoxycarbonyl-4,5-dihydro-3*H*furan-2-one (46a): This compound (74 mg, 73%) was prepared from (*Z*)-31 (100 mg, 0.467 mmol) in a manner analogous to that specified for 39a: $[a]_{\rm D} = -27.9$ (c = 1.1 in CHCl₃); $t_{\rm r}(4S,5S) = 40.93$ min, $t_{\rm r}(4R,5R) = 42.18$ min (126 °C, 100 kPa); 30% *ee*; elemental analysis calcd. (%) for C₁₀H₁₆O₅ (216.2): C 55.56, H 7.46; found: C 55.31, H 7.35.

(4*R*,5*R*)-4-Hydroxy-5-isobutyl-4-methoxycarbonyl-4,5-dihydro-3*H*furan-2-one (46b): This compound (72 mg, 71%) was prepared from (*Z*)-31 (100 mg, 0.467 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: $[a]_D = +32.2$ (*c* = 1.2 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 0.92$ (d, $J_{2'-Me,2'} = 6.6$ Hz, 2'-CH₃)*, 0.94 (d, $J_{3',2'} = 6.6$ Hz, 3'-H₃)*, 1.31– 1.37 (m, 1'-H¹), 1.70–1.81 (m, 1'-H², 2'-H), AB signal ($\delta_A = 2.69$, $\delta_B = 3.15$, $J_{AB} = 17.4$, B part additionally split by ${}^4J_{B,4-OH} = 1.1$ Hz,

3-H₂), 3.44 (br. d, ${}^{4}J_{4-\text{OH},3-\text{H(B)}} = 1.1$ Hz, 4-OH), 3.88 (s, CO₂CH₃), 4.64 (dd, $J_{5,1'-\text{H(2)}} = 9.1$, $J_{5,1'-\text{H(1)}} = 4.0$ Hz, 5-H) ppm; * = interchangeable. IR (film): $\tilde{v} = 3470$, 2960, 2875, 1790, 1745, 1470, 1440, 1410, 1390, 1370, 1355, 1300, 1265, 1220, 1195, 1135, 1105, 1065, 1035, 985, 955 cm⁻¹; $t_r(4R,5R) = 42.53$ min, $t_r(4S,5S) = 41.52$ min (125 °C, 100 kPa); 41% ee.

(4*S*,5*S*)-4-Hydroxy-4-methoxycarbonyl-5-phenyl-4,5-dihydro-3*H*-furan-2-one (47a): This compound (95 mg, 47%) was prepared from (*Z*)-33 (200 mg, 0.854 mmol) in a manner analogous to that specified for 39a: $[a]_D = -36.5$ (c = 1.0 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 2.59$ (d, ${}^4J_{4-OH,3-H(B)} = 2.0$ Hz, 4-OH), AB signal ($\delta_A = 2.89$, $\delta_B = 3.37$, $J_{AB} = 17.3$, B part additionally split by $J_{B,4-OH} = 2.0$ Hz, 3-H₂), 3.92 (s, CO₂CH₃), 5.68 (s, 5-H), 7.23–7.27 and 7.39–7.43 (2×m, C₆H₅) ppm. IR (KBr): $\tilde{v} = 3480$, 3065, 3015, 2955, 1795, 1725, 1455, 1435, 1410, 1330, 1320, 1295, 1260, 1220, 1195, 1155, 1110, 1085, 1015, 770, 700, 500 cm⁻¹; $t_r(4S,5S) = 25.33$ min, $t_r(4R,5R) = 23.89$ min (160 °C, 100 kPa); 72% ee; elemental analysis calcd. (%) for C₁₂H₁₂O₅ (236.2): C 61.01, H 5.12; found C 60.88, H 5.28.

(4*R*,5*R*)-4-Hydroxy-4-methoxycarbonyl-5-phenyl-4,5-dihydro-3*H*furan-2-one (47b): This compound (77 mg, 38%; mp. 79 °C) was prepared from (*Z*)-33 (200 mg, 0.854 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: colorless solid (m.p. 79 °C). [*a*]_D = +16.3 (*c* = 1.0 in CHCl₃); *t*_r(4*R*,5*R*) = 23.93 min, *t*_r(4*S*,5*S*) = 25.40 min (160 °C, 100 kPa); 61% *ee*.

(4*S*,5*S*)-4-Ethoxycarbonyl-4-hydroxy-5-phenyl-4,5-dihydro-3*H*furan-2-one (48a): This compound (46 mg, 49%) was prepared from (*Z*)-34 (98 mg, 0.37 mmol) in a manner analogous to that specified for 39a: $[a]_D = -25.4$ (c = 0.8 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 1.38$ (tm_c, $J_{vic} = 7.2$ Hz, CO₂CH₂CH₃), AB signal (δ_A = 2.88, $\delta_B = 3.37$, $J_{AB} = 17.2$ Hz, 3-H₂), 4.37 (m_c, CO₂CH₂CH₃), 5.67 (s, 5-H), 7.24–7.27 and 7.38–7.43 (2 m, C₆H₅) ppm. IR (CHCl₃): $\tilde{v} = 3545$, 3035, 3030, 3015, 2990, 2940, 1795, 1740, 1455, 1405, 1370, 1316, 1270, 1220, 1180, 1105, 1085, 1035, 1020, 875, 860, 795 cm⁻¹; $t_r(4S,5S) = 48.35$ min, $t_r(4R,5R) = 46.04$ min (160 °C, 100 kPa); 50% *ee*; elemental analysis calcd. (%) for C₁₃H₁₄O₅ (250.2): C 62.39, H 5.64; found: C 62.33, H 5.74.

(4*R*,5*R*)-4-Ethoxycarbonyl-4-hydroxy-5-phenyl-4,5-dihydro-3*H*furan-2-one (48b): This compound (39 mg, 66%; mp. 79 °C) was prepared from (*Z*)-34 (62 mg, 0.24 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: colorless solid (m.p. 79 °C). $[a]_D = +16.3$ (c = 1.0 in CHCl₃); $t_r(4R,5R)$ = 45.73 min, $t_r(4S,5S) = 48.17$ min (150 °C, 100 kPa); 44% *ee*.

(4R,5S)-4-Hydroxy-5-isobutyl-4-methoxycarbonyl-4,5-dihydro-3Hfuran-2-one (49a): This compound (81 mg, 89%) was prepared from (E)-31 (90 mg, 0.42 mmol) in a manner analogous to that specified for **39a**: colorless solid (m.p. 62 °C). $[a]_D = -93.9$ (c = 1.0 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 0.93$ (d, $J_{2'-Me,2'} =$ 6.6 Hz 2'-CH₃)*, 0.95 (d, $J_{3',2'}$ = 6.6 Hz, 3'-H₃)*, AB signal (δ_A = 1.30, $\delta_{\rm B}$ = 1.38, $J_{\rm AB}$ = 14.1 Hz, A part additionally split by $J_{{\rm A},2'}$ = 8.6, $J_{A,5} = 3.0$, B part additionally split by $J_{B,5} = 10.2$, $J_{B,2'} =$ 5.4 Hz, 1'-H₂), 1.82 (m_c, 2'-H), AB signal (δ_A = 2.84, δ_B = 2.95, $J_{AB} = 17.4 \text{ Hz}, 3-\text{H}_2$, 3.65 (s, 4-OH), 3.87 (s, CO₂CH₃), 4.40 (dd, $J_{5,1'-H(B)} = 10.5 \text{ Hz}, J_{5,1'-H(A)} = 3.1 \text{ Hz}, 5-\text{H}) \text{ ppm}; * = \text{interchange-}$ able. IR (CHCl₃): v = 3530, 3355, 3035, 3010, 2960, 2940, 2910, 2875, 1785, 1740, 1470, 1440, 1415, 1295, 1245, 1175, 1140, 1100, 990 cm⁻¹; $t_r(4R,5S) = 12.94 \text{ min}, t_r(4S,5R) = 14.60 \text{ min} (135 °C)$ 100 kPa); 63% ee, elemental analysis calcd. (%) for $C_{10}H_{16}O_5$ (216.2): C 55.56, H 7.46; found: C 55.53, H 7.59.

(4*S*,5*R*)-4-Hydroxy-5-isobutyl-4-methoxycarbonyl-4,5-dihydro-3*H*-furan-2-one (49b): This compound (89 mg, 88%) was prepared from

(*E*)-**31** (100 mg, 0.47 mmol) in a manner analogous to that specified for **39a** but with (DHQD)₂PHAL as a ligand: $[a]_D = +120.8$ (*c* = 0.9 in CHCl₃); $t_r(4S,5R) = 14.15$ min, $t_r(4R,5S) = 12.71$ min (135 °C, 100 kPa); 78% *ee*.

(4*R*,5*S*)-4-Hydroxy-4-methoxycarbonyl-5-phenyl-4,5-dihydro-3*H*-furan-2-one (50a): This compound (71 mg, 70%) was prepared from (*E*)-33 (100 mg, 0.427 mmol) in a manner analogous to that specified for 39a: $[a]_D = -52.2$ (c = 0.6 in CHCl₃); $t_r(4R,5S) = 18.37$ min, $t_r(4S,5R) = 17.48$ min (160 °C, 100 kPa); 82% *ee*.

(4*S*,5*R*)-4-Hydroxy-4-methoxycarbonyl-5-phenyl-4,5-dihydro-3*H*-furan-2-one (50b): This compound (78 mg, 77%) was prepared from (*E*)-33 (100 mg, 0.427 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: colorless solid (m.p. 86 °C). $[a]_D = +58.7 (c = 1.0 \text{ in CHCl}_3)$. ¹H NMR (500 MHz, CDCl₃): $\delta = AB$ signal ($\delta_A = 3.02$, $\delta_B = 3.11$, $J_{AB} = 17.5$ Hz, 3-H₂), 3.47 (s, CO₂CH₃), 3.90 (s, 4-OH), 5.47 (s, 5-H), 7.30–7.35 (m, C₆H₅) ppm. IR (CHCl₃): $\tilde{v} = 3505$, 3395, 3005, 2955, 2930, 1795, 1750, 1495, 1455, 1440, 1275, 1240, 1225, 1215, 1175, 1150, 1080, 1040, 1025, 975, 860, 750, 700, 630, 550 cm⁻¹; $t_r(4S,5R) = 17.50 \text{ min}$, $t_r(4R,5S) = 18.45 \text{ min}$ (160 °C, 100 kPa); 87% *ee*; elemental analysis calcd. (%) for C₁₂H₁₂O₅ (236.2): C 61.01, H 5.12; found: C 60.87, H 5.18.

(4*R*,5*S*)-4-Ethoxycarbonyl-4-hydroxy-5-phenyl-4,5-dihydro-3*H*furan-2-one (51a): This compound (72 mg, 76%) was prepared from (*E*)-34 (100 mg, 0.38 mmol) in a manner analogous to that specified for 39a: colorless solid (m.p. 108 °C). $[a]_D = -40.3$ (c = 1.1 in CHCl₃). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.02$ (t, $J_{vic} = 7.2$ Hz, CO₂CH₂CH₃), AB signal ($\delta_A = 3.01$, $\delta_B = 3.10$, $J_{AB} = 17.3$ Hz, 3-H₂), 3.81 (dq, $J_{gem} = 10.6$ Hz, $J_{vic} = 7.2$ Hz, 1'-H¹), 3.96 (dq, $J_{gem} = 10.7$ Hz, $J_{vic} = 7.1$ Hz, 1'-H²), superimposed by 3.97 (s, 4-OH), 5.49 (s, 5-H), 7.32–7.37 (m, Ph-H) ppm. IR (KBr): $\tilde{v} = 3570$, 3515, 3090, 3065, 3035, 3025, 3020, 3010, 2985, 2940, 2910, 1800, 1735, 1455, 1415, 1320, 1270, 1240, 1165, 1135, 1040, 1025, 860, 780 cm⁻¹; $t_r(4R,5S) = 32.83$ min, $t_r(4S,5R) = 31.97$ min (150 °C, 100 kPa); 84% *ee*; elemental analysis calcd. (%) for C₁₃H₁₄O₅ (250.2): C 62.41, H 5.64; found: C 62.20, H 5.64.

(4*S*,5*R*)-4-Ethoxycarbonyl-4-hydroxy-5-phenyl-4,5-dihydro-3*H*furan-2-one (51b): This compound (79 mg, 83%) was prepared from (*E*)-34 (100 mg, 0.38 mmol) in a manner analogous to that specified for 39a but with (DHQD)₂PHAL as a ligand: $[a]_D = +43.9$ (c = 1.0in CHCl₃); $t_r(4S,5R) = 30.98$ min, $t_r(4R,5S) = 32.58$ min (150 °C, 100 kPa); 90% ee.

Compounds 52a and 52b: These compounds were obtained as described in ref.^[8]

(4*S*,5*S*)-5-[(3*S*)-3,4-Dihydroxy-4-methylpentyl]-4-hydroxy-5methyl-4,5-dihydro-3*H*-furan-2-one (53a): This compound (146 mg, 62%) was prepared from (*E*)-18 (200 mg, 1.02 mmol) in a manner analogous to that specified for **39a**, but twice as much of each reagent was used: ¹H NMR (300 MHz, D₂O): $\delta = 1.24$ (s, 4'-CH₃, 5'-H₃), 1.37–1.51 (m, 2'-H¹)*, superimposed by 1.44 (s, 5-CH₃), 1.76– 1.88 (m, 1'-H¹, 2'-H²)*, 2.10–2.20 (m, 1'-H²)*, 2.61 (dd, $J_{gem} =$ 18.5 Hz, $J_{3-H(1),4} = 2.1$ Hz, $3-H^1$), 3.30 (dd, $J_{gem} = 18.5$ Hz, $J_{3-H(2),4} = 6.2$ Hz, $3-H^2$), 3.43 (dd, $J_{3',2'-H(1)} = 10.6$ Hz, $J_{3',2'-H(2)} =$ 1.6 Hz, 3'-H), 4.41 (dd, $J_{4,3-H(2)} = 6.2$ Hz, $J_{4,3-H(1)} = 2.2$ Hz, 4-H) ppm; * = assignments interchangeable. IR (KBr): $\tilde{v} = 3410$, 2980, 2940, 2880, 1775, 1740, 1460, 1450, 1440, 1415, 1390, 1295, 1215, 1185, 1165, 1090, 1070, 1020, 995, 950, 885, 795 cm⁻¹. This solid was too sparingly soluble for accurate determination of [*a*]_D.

(4R,5R)-5-[(3R)-3,4-Dihydroxy-4-methylpentyl]-4-hydroxy-5methyl-4,5-dihydro-3*H*-furan-2-one (53b): This compound (135 mg, 75%) was prepared from (*E*)-18 (152 mg, 0.774 mmol) in a manner analogous to that specified for **39a**, but twice as much of each reagent and (DHQD)₂PHAL as a ligand was used: colorless solid (m.p. 128 °C); elemental analysis calcd. (%) for $C_{11}H_{20}O_5$ (232.2): C 56.89, H 8.68; found: C 56.70, H 8.76. This solid was too sparingly soluble for accurate determination of $[a]_D$.

Compounds 54a and 54b: These compounds were obtained as described in ref. $\ensuremath{^{[8]}}$

(4*S*,5*R*)-5-[(3*S*)-3,4-Dihydroxy-4-methylpentyl]-4-hydroxy-5methyl-4,5-dihydro-3*H*-furan-2-one (55a): This compound (556 mg, 77%) was prepared from (*Z*)-18 (609 mg, 3.10 mmol) in a manner analogous to that specified for 39a, but twice as much of each reagent was used: ¹H NMR [500 MHz, D₂O, (CD₃)₂CO]: δ = 1.22 and 1.23 (2 s, 4'-CH₃, 5'-H₃), 1.43–1.51 (m, 2'-H¹)*, superimposed by 1.46 (s, 5-CH₃), 1.76–1.79 (m, 1'-H¹, 2'-H²), 1.92–1.99 (m, 1'-H²)**, 2.63 (dd, J_{gem} = 18.5 Hz, J_{3-H(1),4} = 3.4 Hz, 3-H¹), 3.22 (dd, J_{gem} = 18.5 Hz, J_{3-H(2),4} = 6.7 Hz, 3-H²), 3.38 (dd, J_{3',2'-H(1)} = 10.6 Hz, J_{3',2'-H(2)} = 1.4 Hz, 3'-H), 4.41 (dd, J_{4,3-H(2)} = 6.7 Hz, J_{4,3-H(1)} = 3.3 Hz, 4-H) ppm; *. ** = assignable by a C,H correlation spectrum. IR (KBr): \tilde{v} = 3415, 2985, 2965, 2945, 2910, 2875, 2530, 2505, 2475, 1750, 1450, 1385, 1295, 1255, 1180, 1150, 1105, 1065, 1030, 1020, 945, 895, 810, 720, 630 cm⁻¹. This solid was too sparingly soluble for accurate determination of [*a*]_D.

(4*R*,5*S*)-5-[(3*R*)-3,4-Dihydroxy-4-methylpentyl]-4-hydroxy-5methyl-4,5-dihydro-3*H*-furan-2-one (55b): This compound (300 mg, 84%) was prepared from (*Z*)-18 (300 mg, 1.53 mmol) in a manner analogous to that specified for 39a, but twice as much of each reagent and (DHQD)₂PHAL as a ligand were used: colorless solid (m.p. 133 °C); elemental analysis calcd. (%) for $C_{11}H_{20}O_5$ (232.2): C 56.88, H 8.68; found: C 56.83, H 8.52. This solid was too sparingly soluble for accurate determination of $[a]_D$.



(3aS,7aS)-5-Hydroxy-7a-methyl-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-one (56a): NaIO₄ (370 mg, 1.73 mmol, 1.1 equiv.) was added to a solution of 53a (365 mg, 1.57 mmol) in H₂O (18 mL) and THF (1.8 mL). After the mixture had been stirred for 2 h, aq. NH₄Cl (10 mL) was added. The mixture was extracted with CH_2Cl_2 (5×15 mL) and the combined organic extracts were dried with MgSO₄. Evaporation in vacuo and flash chromatography (cyclohexane/EtOAc, 1:3) afforded the title compound [174 mg, 64%; dr 79:21 (Dia-A:Dia-B)]: colorless solid (m.p. 132 °C). [a]_D = -94.5 $(c = 1.0 \text{ in CHCl}_3)$. ¹H NMR (500 MHz, CDCl₃): $\delta = 1.30$ (s, 7a-CH3; Dia-B), 1.32 (s, 7a-CH3; Dia-A), 1.56-1.81, 1.88-1.95, 2.00-2.07, and 2.27-2.30 (4 m, 6-H₂ and 7-H₂; Dia-A and Dia-B), AB signal ($\delta_A = 2.43$, $\delta_B = 2.88$, $J_{AB} = 17.7$, B part additionally split by $J_{B,3a}$ = 4.8 Hz, 3-H₂; Dia-A), AB signal (δ_A = 2.57, δ_B = 2.88, $J_{AB} = 17.6 \text{ Hz}$, B part additionally split by $J_{B,3a} = 4.5 \text{ Hz}$, 3-H₂; Dia-B), 3.03 (m_c, 5-OH; Dia-A), 3.34 (br.d, J_{5-OH.5} = 7.4 Hz, 5-OH; Dia-B), 4.18 (d, J_{3a,3-H(B)} = 4.5 Hz, 3a-H; Dia-B), 4.32 (d, $J_{3a,3-H(B)} = 4.8$ Hz; Dia-A), 4.76 (m_c, presumably interpretable as ddd, $J_{5,6-H(1)} = 8.9$ Hz, $J_{5,5-OH} = 7.2$ Hz, $J_{5,6-H(2)} = 1.8$ Hz, 5-H; Dia-B), 5.25 (q, $J_{5,5-OH} = J_{5,6-H(1)} = J_{5,6-H(2)} = 3.2$ Hz, 5-H; Dia-A) ppm. IR (film): v = 3425, 2990, 2970, 2965, 2950, 1745, 1725, 1445, 1430, 1385, 1340, 1320, 1275, 1195, 1120, 1090, 1045, 1000, 955, 940, 825, 790, 595 cm⁻¹; elemental analysis calcd. (%) for C₈H₁₂O₄ (172.1): C 55.81, H 7.03; found: C 55.70, H 6.92.

(3a*R*,7a*R*)-5-Hydroxy-7a-methyl-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-one (56b): This compound (120 mg, 72%; *dr* 79:21) was prepared from 53b (224 mg, 0.964 mmol) in a manner analogous to that specified for 56a: $[a]_D = +90.6$ (c = 1.1 in CHCl₃).



(3aS,7aS)-7a-Methyl-3a,6,7,7a-tetrahydrofuro[3,2-b]pyran-2,5-(3H)dione (57a): Pyridinium chlorochromate (571 mg, 2.65 mmol, 2.0 equiv.) was added to a solution of 56a (228 mg, 1.32 mmol) in CH₂Cl₂ (10 mL). After stirring overnight, the mixture was filtered through Celite, evaporated in vacuo, and purified by flash chromatography (cyclohexane/EtOAc, 1:2) to afford the title compound (129 mg, 57%): colorless solid (m.p. 129 °C). $[a]_D = -19.2$ $(c = 1.1 \text{ in CHCl}_3)$. ¹H NMR (500 MHz, CDCl₃): $\delta = 1.51$ (s, 7a-CH₃), AB signal (δ_A = 2.17, δ_B = 2.30, J_{AB} = 14.5 Hz, A part additionally split by $J_{A,6-H(B)} = 9.8$ Hz, $J_{A,6-H(A)} = 4.8$ Hz, B part additionally split by $J_{B,6-H(A)} = 7.3$, $J_{B,6-H(B)} = 5.0$ Hz, 7-H₂), AB signal ($\delta_A = 2.49, \delta_B = 2.65, J_{AB} = 17.2$, A part additionally split by $J_{A,7-H(B)} = 7.3$ Hz, $J_{A,7-H(A)} = 4.8$ Hz, B part additionally split by $J_{B,7-H(A)} = 9.8$ Hz, $J_{B,7-H(B)} = 4.9$ Hz, 6-H₂), AB signal ($\delta_A =$ 2.82, $\delta_{\rm B}$ = 3.09, $J_{\rm AB}$ = 18.9 Hz, B part additionally split by $J_{\rm B,3a}$ = 6.4 Hz, 3-H₂), 4.79 (dd, $J_{3a,3-H(B)} = 6.5$ Hz, $J_{3a,3-H(A)} = 0.6$ Hz, 3a-H) ppm. IR (film): $\tilde{v} = 2980, 2945, 2885, 1780, 1760, 1750, 1455,$ 1435, 1410, 1385, 1315, 1285, 1240, 1225, 1185, 1155, 1100, 1050, 985, 950, 880, 805, 695, 625, 565, 535 cm⁻¹; $t_r(3aS,7aS) =$ $15.19 \min_{r} t_r(3aR, 7aR) = 14.19 \min(150 \text{ °C}, 100 \text{ kPa}); 83\% ee; ele$ mental analysis calcd. (%) for C₈H₁₀O₄ (170.2): C 56.47, H 5.92; found: C 56.53, H 5.79.

(3a*R*,7a*R*)-7a-Methyl-3a,6,7,7a-tetrahydrofuro[3,2-*b*]pyran-2,5-(3*H*)-dione (57b): This compound (63 mg, 63%) was prepared from 56b (102 mg, 0.592 mmol) in a manner analogous to that specified for 57a: $[a]_D = +20.1$ (c = 0.7 in CHCl₃); $t_r(3aR,7aR) = 13.66$ min, $t_r(3aS,7aS) = 14.76$ min (150 °C, 100 kPa); 82% *ee.*

(4*S*,5*R*)-4-Hydroxy-5-methyl-5-(3-oxopropionyl)-4,5-dihydro-3*H*furan-2-one (58a): H₂O (0.3 mL) was added to a suspension of 55a (72 mg, 0.31 mmol), EtOAc (6 mL), and NaIO₄ (73 mg, 0.34 mmol, 1.1 equiv.). After 30 min, EtOAc (20 mL) was added. The mixture was dried with MgSO₄, evaporated in vacuo, and purified by flash chromatography (EtOAc) to afford the title compound (50 mg, 94%): $[a]_D = +8.0$ (c = 1.0 in CHCl₃).

(4R,5S)-4-Hydroxy-5-methyl-5-(3-oxopropionyl)-4,5-dihydro-3Hfuran-2-one (58b): This compound (197 mg, 91%) was prepared from 55b (292 mg, 1.26 mmol) in a manner analogous to that specified for **58a**: $[a]_{D} = -8.8$ (c = 1.0 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ = 1.38 (s, 5-CH₃), AB signal (δ _A = 1.93, δ _B = 1.98, J_{AB} = 14.7 Hz, A part additionally split by $J_{A,2'-H(B)}$ = 8.4 Hz, $J_{A,2'-H(B)}$ $_{\rm H(A)}$ = 6.4 Hz, B part additionally split by $J_{\rm B,2'-H(A)}$ = 8.3 Hz, $J_{\rm B,2'-H(A)}$ $_{H(B)}$ = 6.4 Hz, 1'-H₂), 2.29 (br.s, 4-OH), AB signal (δ_{A} = 2.58, δ_{B} = 2.93, J_{AB} = 18.0 Hz, A part additionally split by $J_{A,4}$ = 4.8 Hz, B part additionally split by $J_{B,4} = 6.9$ Hz, 3-H₂), AB signal ($\delta_A =$ 2.66, $\delta_{\rm B}$ = 2.70, $J_{\rm AB}$ = 18.7 Hz, A part additionally split by $J_{\rm A,1'}$. $_{H(B)}$ = 8.3 Hz, $J_{A,1'-H(A)}$ = 6.5 Hz, $J_{A,3'}$ = 0.9 Hz, B part additionally split by $J_{B,1'-H(A)} = 8.3 \text{ Hz}$, $J_{B,1'-H(B)} = 6.4 \text{ Hz}$, $J_{B,3'} = 0.8 \text{ Hz}$, 2'-H₂), 4.25 (br. dd, $J_{4,3-H(B)} = 6.8$ Hz, $J_{4,3-H(A)} = 4.8$ Hz, 4-H), 9.82 (m_c, 3'-H) ppm. IR (film): $\tilde{v} = 3430, 2985, 2940, 2845, 2735, 1770,$ 1725, 1440, 1415, 1385, 1300, 1260, 1195, 1170, 1110, 1095, 1075,

1045, 945, 800 cm⁻¹; elemental analysis calcd. (%) for $C_8H_{12}O_4$ (172.1): C 55.81, H 7.02; found: C 55.69, H 7.04.

(4S,5R)-5-But-3-enyl-4-hydroxy-5-methyl-4,5-dihydro-3H-furan-2one (59a): n-BuLi (2.3 M hexane, 0.28 mL, 0.64 mmol, 1.4 equiv.) was added at -5 °C to a suspension of triphenylmethylphosphonium bromide (266 mg, 0.744 mmol, 1.6 equiv.) in THF (2 mL). The mixture was allowed to reach room temperature. After stirring for 1 h, the mixture was cooled to -5 °C and a solution of 58a (80 mg, 0.47 mmol) in THF (2 mL) was added. The mixture was allowed to reach room temperature and stirred for 1.5 h. Aq. NH₄Cl (10 mL) was added and the mixture was extracted with EtOAc (4×20 mL) and dried with MgSO₄. Evaporation in vacuo and purification by flash chromatography (cyclohexane/EtOAc, 2:1) afforded the title compound (25 mg, 31%): $[a]_{D} = +1.1$ (c = 0.6 in CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 1.40$ (s, 5-CH₃), 1.65–1.77 (m, 1'-H₂)*, 2.11–2.24 (m, 2'-H₂)*, AB signal ($\delta_A = 2.56$, $\delta_{\rm B}$ = 2.91, $J_{\rm AB}$ = 18.0, A part additionally split by $J_{\rm A,4}$ = 4.3, B part additionally split by $J_{B,4} = 7.0$ Hz, 3-H₂), A part superimposed 2.56 (br.s, 4-OH), 4.27 (dd, $J_{4,3-H(B)} = 6.9$, $J_{4,3-H(A)} = 4.3$ Hz, 4-H), 4.99 (dm_c, 4'-H¹), 5.05 (dm_c, 4'-H²), 5.79 (dddd, $J_{trans} = 17.0$, $J_{cis} = 10.4$, $J_{3',2'-H(1)} = J_{3',2'-H(2)} = 6.6$ Hz, 3'-H) ppm; * = assignable by a C,H correlation spectrum. IR (film): $\tilde{v} = 3440$, 3080, 2980, 2940, 2860, 1755, 1640, 1450, 1415, 1385, 1300, 1260, 1200, 1175, 1065, 1000, 950, 920, 795 cm⁻¹; $t_r(4S, 5R) = 13.25 \text{ min}$, $t_r(4R,5S) = 14.32 \text{ min } (135 \text{ °C}, 100 \text{ kPa}); 90\% ee;$ elemental analysis calcd. (%) for C₉H₁₄O₃ (232.2): C 63.51, H 8.29; found: C 63.23, H 8.42

(4*R*,5*S*)-5-(But-3-enyl)-4-hydroxy-5-methyl-4,5-dihydro-3*H*-furan-2one (59b): This compound (49 mg, 36%) was prepared from 58b (139 mg, 0.807 mmol) in a manner analogous to that specified for 59a: $[a]_D = -1.2$ (c = 1.1 in CHCl₃); $t_r(4R,5S) = 14.16$ min, $t_r(4S,5R) = 13.28$ min (150 °C, 100 kPa); 93% *ee*.

Acknowledgments

This work was financially supported by the Fonds der Chemischen Industrie. We express our gratitude to Valentina Morgel for her skilful technical assistance.

- [1] Recent isolations of γ -lactone natural products: a) Y.-W. Guo, M. Gavagnin, E. Mollo, E. Trivellone, G. Cimino, J. Nat. Prod. 1999, 62, 1194-1196; b) K. W. Cho, H.-S. Lee, J.-R. Rho, T. S. Kim, S. J. Mo, J. Shin, J. Nat. Prod. 2001, 64, 664-667; c) R. Ratnayake, V. Karunaratne, B. M. Ratnayake Bandara, V. Kumar, J. Nat. Prod. 2001, 64, 376-378; d) S. M. Hein, J. B. Gloer, B. Koster, D. Malloch, J. Nat. Prod. 2001, 64, 809-812; e) J. S. Sandler, P. L. Colin, J. N. A. Hooper, D. J. Faulkner, J. Nat. Prod. 2002, 65, 1258–1261; f) D. S. Ming, A. Lopez, B. J. Hillhouse, C. J. French, J. B. Hudson, G. H. N. Towers, J. Nat. Prod. 2002, 65, 1412-1416; g) B. S. Min, S. Y. Lee, J. H. Kim, O. K. Kwon, B. Y. Park, R. B. An, J. K. Lee, H. I. Moon, T. J. Kim, Y. H. Kim, H. Joung, H. K. Lee, J. Nat. Prod. 2003, 66, 1388-1390; h) S. P. Gunasekera, R. A. Isbrucker, R. E. Longley, A. E. Wright, S. A. Pomponi, J. K. Reed, J. Nat. Prod. 2004, 67, 110-111.
- [2] Recent syntheses of enantiomerically pure butanolides include the following: a) A. Samarat, H. Amri, Y. Landais, *Tetrahedron* 2004, 60, 8949–8956; b) P. R. Krishna, V. V. R. Reddy, G. V. M. Sharma, *Synthesis* 2004, 2107–2114; N. J. Kerrigan, P. C. Hutchison, T. D. Heightman, D. J. Procter, *Org. Biomol. Chem.* 2004, 2, 2476–2482; c) P. V. Ramachandran, D. Pratihar, D. Biswas, A. Srivastava, M. V. R. Reddy, *Org. Lett.* 2004, 6, 481–484; d) L. Thijs, B. Zwanenburg, *Tetrahedron* 2004, 6, 4207–5252; e) L. Wang, P. E. Floreancig, *Org. Lett.* 2004, 6, 4207–

4210; f) C. M. Rodríguez, J. L. Ravelo, V. S. Martín, Org. Lett. 2004, 6, 4787-4789; g) N. J. Kerrigan, T. Upadhyay, D. J. Procter, Tetrahedron Lett. 2004, 45, 9087-9090; h) A. Samarat, H. Amri, Y. Landais, Tetrahedron 2004, 60, 8949-8956; i) S. T. Taylor, C. R. Arnold, A. T. Gerds, N. D. Ide, K. M. Law, D. L. Kling, M. G. Pridgeon, L. J. Simons, J. R. Vyvyan, J. S. Yamaoka, M.-K. Liao, T. E. Goyne, Tetrahedron Asym. 2004, 15, 3819-3821; j) S. Behr, K. Hegemann, H. Schomanski, R. Fröhlich, G. Haufe, Eur. J. Org. Chem. 2004, 3884-3892; k) K. Shimoda, N. Kubota, Tetrahedron Asym. 2004, 15, 3827-3829; 1) K. Kiegiel, T. Balakier, P. Kwiatkowski, J. Jurczak, Tetrahedron Asym. 2004, 15, 3869-3878; m) L.-L. Huang, M.-H. Xu, G.-Q. Lin, J. Org. Chem. 2005, 70, 529-532; n) M. He, A. Lei, X. Zhang, Tetrahedron Lett. 2005, 46, 1823-1826; o) B. Nay, N. Gaboriaud-Kolar, B. Bodo, Tetrahedron Lett. 2005, 46, 3867-3870; p) E. A. Bercot, D. E. Kindrachuk, T. Rovis, Org. Lett. 2005, 7, 107-110; q) S. Takahashi, N. Ogawa, N. Sakairi, T. Nakata, Tetrahedron 2005, 61, 6540-6545.

- [3] Recent syntheses of enantiomerically pure Δ³-butenolides include the following: a) Y. Isemori, Y. Kobayashi, *Synlett* 2004, *11*, 1941–1944; b) A. Kirschner, P. Langer, U. T. Bornscheuer, *Tetrahedron: Asymmetry* 2004, *15*, 2871–2874; c) M. Braun, A. Hohmann, J. Rahematpura, C. Bühne, S. Grimme, *Chem. Eur. J.* 2004, *10*, 4584–4593; d) S.-K. Khim, M. Dai, X. Zhang, L. Chen, L. Pettus, K. Thakkar, A. G. Schultz, *J. Org. Chem.* 2004, *69*, 7728–7733; e) A. M. Montana, F. García, C. Batalla, *Tetrahedron Lett.* 2004, *45*, 8549–8552; f) C.-W. Cho, M. J. Krische, *Angew. Chem.* 2004, *116*, 6857–6859.
- Reviews: a) B. B. Lohray, Tetrahedron: Asymmetry 1992, 3, [4] 1317-1349; b) R. A. Johnson, K. B. Sharpless, Asymmetric Catalysis in Organic Synthesis (Ed.: I. Ojima), VCH Publishers, New York, 1993, 227-272; c) H.C. Kolb, M.S. Van-Nieuwenhze, K. B. Sharpless, Chem. Rev. 1994, 94, 2483-2547; d) G. Poli, C. Scolastico, Methoden Org. Chem. (Houben-Weyl) 4th ed., 1952, Vol. E21e (Eds.: G. Helmchen, R. W. Hoffmann, J. Mulzer, E. Schaumann), Thieme, Stuttgart, 1995, pp. 4547-4598; e) R. A. Johnson, K. B. Sharpless, Catalytic Asymmetric Synthesis, 2nd ed. (Ed.: I. Ojima), Wiley-VCH, New York, 2000, 357-389; f) C. Bolm, J. P. Hildebrand, K. Muniz, Catalytic Asymmetric Synthesis, 2nd ed. (Ed.: I. Ojima), Wiley-VCH, New York, 2000, 399-428. Rationalizations of the absolute configuration of AD products: g) H. C. Kolb, P. G. Andersson, K. B. Sharpless, J. Am. Chem. Soc. 1994, 116, 1278-1291 (empirically); h) N. Moitessier, C. Henry, C. Len, Y. Chapleur, J. Org. Chem. 2002, 67, 7275–7282 (by calculation).
- [5] a) Isolated descriptions: references [5a,6] in ref.^[6]; b) Methodological study: reference [7] in ref.^[6]
- [6] S. Braukmüller, R. Brückner, Eur. J. Org. Chem. 2006, 2110– 2118; preceding article.
- [7] References [8-19] in ref.^[6]
- [8] T. Kapferer, R. Brückner, A. Herzig, W. A. König, *Chem. Eur. J.* 2005, 11, 2154–2162.
- [9] a) T. Martín, V. S. Martín, *Tetrahedron Lett.* 2000, 41, 2503–2505; b) C. García, M. A. Soler, V. S. Martín, *Tetrahedron Lett.* 2000, 41, 4127–4130; c) Y.-T. He, H.-N. Yang, Z.-J. Yao, *Tetrahedron* 2002, 58, 8805–8810.
- [10] Arndt–Eistert homologation review: a) W. E. Bachmann, W. S. Struve, Org. React. 1942, 1, 38–62. Arndt–Eistert homologation of α,β-unsaturated acid chlorides: b) J. A. Moore, J. Org. Chem. 1955, 20, 1607–1612. Syntheses of α,β-unsaturated diazo ketones from α,β-unsaturated acid chlorides (without ensuing Wolff rearrangement): c) M. Berenbom, W. S. Fones, J. Org. Chem. 1949, 14, 1629–1629; d) P. Ceccherelli, M. Curini, M. C. Marcotullio, O. Rosati, J. Org. Chem. 1990, 55, 311–315; e) P. Checcherelli, M. Curini, M. C. Marcotullio, O. Rosati, E. Wenkert, J. Org. Chem. 1991, 56, 7065–7070; f) G. D. Prestwich, I. Ujváry, J. Labelled Comp. Radiopharm. 2002, 2, 37–38.
- [11] Review: B. E. Maryanoff, A. B. Reitz, *Chem. Rev.* 1989, *89*, 863–927; A. Maercker, *Org. React.* 1965, *14*, 270–490.
- [12] References [17] and [18], respectively, in ref.^[8]

- [13] a) Ref.^[10b]; b) J. H. Wotiz, S. N. Buco, J. Org. Chem. 1955, 20, 210–214; c) M. Regitz, F. Menz, A. Liedhegener, Justus Liebigs Ann. Chem. 1970, 739, 174–184; d) A. Nabeya, F. B. Culp, J. A. Moore, J. Org. Chem. 1970, 35, 2015–2021; e) T. Hudlicky, J. P. Shet, Tetrahedron Lett. 1979, 20, 2667–2670; f) E. Muray, A. Alvarez-Larena, J. F. Piniella, V. Branchadell, R. M. Ortuño, J. Org. Chem. 2000, 65, 388–396.
- [14] Wolff rearrangement review:W. Kirmse, Eur. J. Org. Chem. 2002, 2193–2256.
- [15] J. M. Clough, G. Pattenden, *Tetrahedron* 1981, 37, 3911–3920.
- [16] A. Yanagisawa, S. S. Habaue, K. Yasue, H. Yamamoto, J. Am. Chem. Soc. 1994, 116, 6130–6141.
- [17] a) (Trimethylsilyl)diazomethane: D. Seyferth, A. W. Dow, H. Menzel, T. C. Flood, J. Am. Chem. Soc. 1968, 90, 1080–1082;
 D. Seyferth, H. Menzel, A. W. Dow, T. C. Flood, J. Organomet. Chem. 1972, 44, 279–290; U. Schöllkopf, H.-U. Scholz, Synthesis 1976, 271–272; L. A. Paquette (Editor-in-Chief), Encyclopedia of Reagents for Organic Synthesis, vol. 7, John Wiley & Sons, Sussex, England, 1995, 5248–5251; b) Methyl ester formation with (trimethylsilyl)diazomethane: N. Hashimoto, T. Aoyama, T. Shioiri, Chem. Pharm. Bull. 1981, 29, 1475–1478.
- [18] a) T. Okano, N. Okabe, J. Kiji, Bull. Chem. Soc. Jpn. 1992, 65, 2589–2593; b) Y. Imada, O. Shibata, S.-I. Murahashi, J. Organomet. Chem. 1993, 451, 183–194.
- [19] Compounds 22 and 24 described in: C. Wentrup, G. Gross, H.-M. Berstermann, P. Lorenčak, J. Org. Chem. 1985, 50, 2877– 2881; synthesis of ethyl ester analogue of 24: S. Anklam, Dissertation, University of Freiburg, 2003, pp. 185–186.
- [20] Syntheses of compounds 23 and 25: S. Braukmüller, Dissertation, University of Freiburg, 2002, pp. 166–167.
- [21] Syntheses of reagent 21 described, *inter alia*, by: D. E. McGreer, N. W. K. Chiu, *Can. J. Chem.* 1968, 46, 2225–2232;
 D. Hellwinkel, T. Kosack, *Liebigs Ann. Chem.* 1985, 226–238.
- [22] Phosphonate 38 was kindly supplied by Tom Olpp (preparation: T. Olpp, Dissertation, University of Freiburg, 2005, pp. 281–282).
- [23] Different *p.p*-(Aryloxy)-substituted HWE reagents are known to form *a*,β-unsaturated esters (*Z*)-selectively from studies by Ando et al.: a) K. Ando, *Tetrahedron Lett.* **1995**, *36*, 4105–4108; b) K. Ando, *J. Org. Chem.* **1997**, *62*, 1934–1939; c) K. Ando, *J. Org. Chem.* **1998**, *63*, 8411–8416; d) K. Ando, *J. Org. Chem.* **1999**, *64*, 8406–8408; e) K. Ando, T. Oishi, M. Hirama, H. Ohno, T. Ibuka, *J. Org. Chem.* **2000**, *65*, 4745–4749; f) K. Ando, *Synlett* **2001**, 1272–1274.
- [24] W. C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 2923– 2925.
- [25] P. Blundell, A. K. Ganguly, V. M. Girijavallabhan, Synlett 1994, 263–265.
- [26] K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino, J. Hartung, K. S. Jeong, H. L. Kwong, K. Morikawa, Z. M. Wang, D. Xu, X.-L. Zhang, *J. Org. Chem.* **1992**, *57*, 2768–2771.
- [27] Reviews: a) T. K. M. Shing, "Glycol Cleavage Reactions", in: Comprehensive Organic Synthesis (Eds.: B. M. Trost, I. Fleming), 7, 703–716, Pergamon Press, Oxford, 1991; b) A. H. Haines, Methods for the Oxidation of Organic Compounds –

Alcohols, Alcohol Derivates, Alkyl Halides, Nitroalkanes, Alkyl Azides, Carbonyl Compounds, Hydroxyarenes and Aminoarenes, Academic Press, London, **1988**, 277–304; c) Procedure: D. Y. Jackson, Synth. Commun. **1988**, 18, 337–341.

- [28] Precedence for the transformation lactol + PCC → lactone: a)
 T. Fujisawa, T. Itoh, M. Nakai, T. Sato, *Tetrahedron Lett.* 1985, 26, 771–774; b)
 K. Lorenz, F. W. Lichtenthaler, *Tetrahedron Lett.* 1987, 28, 6437–6440; c)
 I. Saito, Y.-H. Kuo, T. Matsuura, *Tetrahedron Lett.* 1986, 27, 2757–2760; d)
 P. A. Grieco, J. L. Collins, E. D. Moher, T. J. Fleck, R. S. Gross, J. Am. Chem. Soc. 1993, 115, 6078–6093.
- [29] The low yield of this reaction is reminiscent of a similar problem with a related Wittig reaction: M. Hizuka, N. Hayashi, T. Kamashita, H. Suemune, K. Sakai, *Chem. Pharm. Bull.* 1988, 36, 1550–1553.
- [30] B. S. Furniss, A. J. Hannaford, P. W. G. Smith, A. R. Tatchell, *Vogel's Textbook of Practical Organic Chemistry*, 5th ed., Longman, Essex, UK, **1989**, 430–432.
- [31] Compound 4a was described previously by: R. C. Larock, J. Org. Chem. 1975, 40, 3237–3242.
- [32] This ylide was prepared by a procedure analogous to that described by: J. E. Baldwin, M. G. Moloney, A. F. Parsons, *Tetrahedron* **1992**, *48*, 9373–9384.
- [33] M. P. Sibi, N. Prabagaran, S. G. Ghorpade, C. P. Jasperse, J. Am. Chem. Soc. 2003, 125, 11796–11797.
- [34] This ylide was prepared by a procedure analogous to that described by: H.-J. Bestmann, H. Hartung, *Chem. Ber.* 1966, 99, 1198–1207.
- [35] P. Kraft, W. Eichenberger, Eur. J. Org. Chem. 2004, 354-365.
- [36] W. Adam, R. Albert, N. D. Grau, L. Hasemann, B. Nestler, E.-M. Peters, F. Prechtl, H. G. v. Schnering, *J. Org. Chem.* 1991, 56, 5778–5781.
- [37] This reagent was prepared as described by: L. Ghosez, I. George-Koch, L. Patiny, M. Houtekie, P. Bovy, P. Nshimyumu-kiza, T. Phan, *Tetrahedron* 1998, 54, 9207–9222.
- [38] Compound (E)-31 was described previously by: R. Ballini, G. Boscia, M. Damiani, P. Righi, *Tetrahedron* 1999, 55, 13451– 13456.
- [39] Compound (Z)-31 was described previously by: K. Yamamoto, R. Deguchi, J. Tsuji, Bull. Chem. Soc. Jpn. 1985, 58, 3397– 3398.
- [40] Compound 32 was described previously by: R. Fittig, J. Kraencker, Justus Liebigs Ann. Chem. 1890, 256, 97–105.
- [41] Compound (E)-33 was described previously by: R. Ballini, G. Bosica, A. Masè, M. Petrini, Eur. J. Org. Chem. 2000, 2927–2931.
- [42] Compound (Z)-33 was described previously by: Y. Shen, Y. Zhang, *Heteroat. Chem.* 2003, 14, 276–279.
- [43] Compound (E)-34 was described previously by: W. I. Awad, N. G. Kandile, W. N. Wassef, N. I. Mohamed, J. Prakt. Chem. 1989, 331, 405–410.
- [44] Compound 41a was described previously by: J. Falbe, H.-J. Schulze-Steinen, F. Korte, *Chem. Ber.* 1964, 97, 1096–1103. Received: December 8, 2005

Published Online: March 8, 2006